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Familial adenomatous polyposis:  
Screening, surgery and desmoid tumours 
 
Background: Familial adenomatous polyposis (FAP) is an autosomal dominant 
inherited syndrome, which is characterized by the development of hundreds or 
thousands of polyps in the colon and rectum. The first representative of the family 
(proband) is usually found because he/she presents with the symptoms that usually 
arise from multiple polyps or from cancer in the large intestine. After this diagnosis 
family members of that proband are called for screening. The prevention of 
otherwise inevitable colorectal cancer by prophylactic surgery should preferably be 
performed in early adulthood. The main surgical options are colectomy with 
ileorectal anastomosis and proctocolectomy with an ileal pouch-anal anastomosis or 
ileostomy. The screening of FAP has been shown to be effective in terms of 
diminishing the number of deaths from colorectal cancer, but the reduction in 
overall mortality remains unclear. Patients with FAP also carry an elevated risk of 
desmoid tumours, which are histologically benign proliferations of myofibroblasts, 
but are often difficult to treat. Desmoid tumours of FAP patients may also act more 
aggressively than their sporadic counterparts.  
 
Aims: The aims of this PhD study were to analyse the short-term and long-term 
outcomes of the two different surgical procedures: colectomy with ileorectal 
anastomosis (IRA) and proctocolectomy with ileal pouch-anal anastomosis (IPAA). 
Further analysis was done on the need and the results of secondary proctectomies 
after IRA. The authors aimed to determine, whether familial screening reduces the 
overall mortality. The causes of death among Finnish FAP patients were studied. 
The risk of FAP among desmoid tumour patients was also studied. The disease 
outcome of patients with FAP-related tumours was compared with that of sporadic 
desmoid tumours in the Finnish population. 
 
Patients and methods: Patient files of all 421 Finnish FAP patients archived 
since the year 1963 were studied. There were a total of 228 patients who had 
undergone IRA or IPAA between years 1963-2012. During the same period, 39 
secondary proctectomies were performed for IRA patients. All the Finnish FAP 
patients until April 30th 2015 were included in the study for which the effect of 
screening was evaluated. Patients with a diagnosis of sporadic desmoid tumours 
between years 2000-2012 in Helsinki University Hospital district were invited to 
the FAP screening. They were offered both endoscopic screening and gene mutation 
testing. All 221 desmoid tumour patients from the year 1980 were included into the 
comparison of treatment between FAP associated and sporadic desmoid tumour. 
 
Results: There were no significant differences in short term complications between 
IRA and IPAA. In the long run, however, more patients in the IRA group ended up 
with ileostomy than in the IPAA group. The total cumulative survival was better 
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after IPAA than IRA, but if the analysis only took into account IRA performed after 
the IPAA era (from the year 1992 onwards) there were no significant difference 
between the groups. Secondary proctectomy was performed on 28% of IRA patients. 
The cumulative risk for secondary proctectomy at 30 years was 53%. The majority of 
operations were performed for cancer or suspicion of cancer. The risk of rectal 
cancer after IRA was 13% and the risk of rectal cancer death was 7%. The crude 
mortality ratio of probands was 34.9 per 1000 person years and 8.3 among call-ups. 
The relative survival of probands was significantly lower than for their call-up 
counterparts, and 20 year relative survival for the call-ups was as high as 94%. Over 
two-thirds of all deaths were FAP related. Among sporadic desmoid tumour patients 
the prevalence of FAP was 4.8%. FAP diagnosis of these patients was evident by 
endoscopy. No cases of AFAP, which could sometimes be detectable only by gene 
mutation testing, were found. There were more intra-abdominal desmoids in the 
FAP desmoid tumour group, and the desmoid tumours were bigger and more often 
multiple than those in the sporadic desmoid tumour group. Majority of sporadic 
desmoid tumour patients were women, whereas among the FAP-related desmoid 
tumour population the gender distribution was equal and the FAP related desmoid 
tumour patients were younger. The treatment of FAP-related desmoids was more 
difficult, intralesional resections were more common and there are desmoid-related 
deaths (14% of all deaths) among FAP patients in contrast to sporadic desmoids. 
 
Conclusions: Patients who underwent IPAA did not have more postoperative 
complications than patients with IRA. Substantial risk of rectal cancer remains after 
colectomy and IRA, so the IPAA procedure should be favored for the FAP patients 
with intermediate or severe polyposis.  The risk of permanent stoma is also higher 
when proctectomy was performed in the second phase. The survival of probands is 
significantly lower than that of the general population whereas that of call-ups was 
comparable to the general population for up to 20 years after diagnosis. This is why 
the screening effort for the family members of the proband must be done. Desmoid 
tumour patients carry an elevated risk of FAP and therefore screening is usually 
indicated. Only asymptomatic patients with desmoid tumours situated in the extra 
truncal region may not need to be routinely screened. Desmoid tumours among FAP 
patients carry a more complex course of disease compared to patients with a 
sporadic desmoids, and thus the treatment of FAP-related desmoids is also more 
complex. If R0 resection is not achieved, the wait-and-see strategy might be a better 




Familiaalinen adenomatoottinen polypoosi: 
Seulonta, kirurgia ja desmoidikasvaimet. 
 
Tausta: Familiaalinen adenomatoottinen polypoosi (FAP) on suvuittain esiintyvä, 
autosomaalisesti vallitsevasti periytyvä oireyhtymä. Sille on ominaista satojen tai 
tuhansien polyyppien esiintyminen paksusuolen alueella. Suvun ensimmäinen jäsen 
havaitaan yleensä polyyppien tai jo kehittyneen syövän aiheuttamien oireiden 
perusteella. Heidän lähisukulaisensa kutsutaan seulontatutkimuksiin ennen 
oireiden alkua. Ilman hoitoa paksusuolen syöpä on lähes väistämätön, ja siksi 
kaikille familiaalista adenomatoottista polypoosia sairastaville suositellaan 
ennaltaehkäisevää kirurgiaa nuorella aikuisiällä. Yleisimmät leikkausvaihtoehdot 
ovat kolektomia ja ileorektaalinen liitos (IRA) tai proktokolektomia ja ileoanaalinen 
liitos (IPAA) ohutsuolen loppuosasta tehtävän säiliön avulla. Seulonnan on todettu 
vähentävän paksusuolensyöpäkuolleisuutta, mutta vaikutus kokonaiskuolleisuuteen 
on epäselvä. Familiaalista adenomatoottista polypoosia sairastavilla on kohonnut 
riski desmoidikasvaimiin. Desmoidikasvaimet ovat histologisesti hyvänlaatuisia, 
mutta toisinaan hankalahoitoisia. FAP potilaiden desmoidikasvaimet saattavat olla 
aggressiivisempia kuin desmoidikasvaimet, jotka esiintyvät erillään FAP:sta.  
 
Tavoitteet: Tämän väitöskirjatutkielman tavoitteena oli arvioida eri 
leikkausmenetelmien (kolektomia ja ileorektaalinen liitos, ja proktokolektomia ja 
ileoanaalinen liitos) lyhyt- ja pitkäaikaistuloksia. Arvioimme kolektomiaryhmän 
potilaiden riskiä ajautua myöhemmin peräsuolen poistoon, ja myöhemmin tehtävän 
peräsuolen poiston tuloksia. Tavoitteenamme oli selvittää, vaikuttaako seulonta 
kokonaiskuolleisuuteen. Lisäksi selvitimme suomalaisten FAP-potilaiden 
kuolinsyyt. Desmoidikasvainpotilaiden riskiä sairastua FAP:iin tutkittiin.  
Sporadisesti esiintyvien ja FAP:iin liittyvien desmoidikasvaimien taudinkulkua 
verrattiin.  
 
Potilaat ja menetelmät: Kaikki tunnetut suomalaiset 421 FAP-potilasta otettiin 
mukaan tutkimukseen vuodesta 1963 alkaen. Yhteensä 228 paksusuolen poistoa ja 
ileorektaalista tai ileoanaalista liitosta oli tehty 1963–2012. Samana aikana 39 
myöhempää peräsuolen poistoa tehtiin ileorektaalisen ryhmän potilaille. Kaikki 
tunnetut FAP-potilaat otettiin tutkimukseen jossa selvitettiin seulonnan vaikutusta 
eloonjäämiseen. Potilaat, joilla oli todettu desmoidikasvain vuosien 2000–2012 
välillä, kutsuttiin FAP seulontaan. Heille tarjottiin sekä tähystys että geenitesti, 
mikäli näitä ei ollut aiemmin tehty. Kaikki 221 desmoidikasvaimeen vuoden 1980 
jälkeen sairastunutta potilasta otettiin mukaan tutkimukseen, jossa FAP:iin 
liittyvien ja sporadisten desmoidikasvaimien hoitoa verrattiin. 
 
Tulokset: Lyhyen aikavälin komplikaatioissa ei ollut IRA- ja IPAA-ryhmien välillä 
eroa. IRA-ryhmässä useampi potilas päätyi pysyvään avanteeseen. IPAA-ryhmässä 
oli kokonaisuudessaan parempi eloonjäämisen ennuste, mutta mikäli otettiin 
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huomioon vain IPAA-aikakaudella tehdyt leikkaukset (vuodesta 1992 alkaen), 
merkittävää eroa ei havaittu. Myöhempi peräsuolen poisto tehtiin 28%:lle IRA 
potilaista. Kumulatiivinen riski myöhempään peräsuolen poistoon oli 53% 30 
vuoden aikana. Suurin osa myöhemmistä peräsuolen poistoista tehtiin syövän tai 
syöpäepäilyn vuoksi. Peräsuolisyövän riski IRA:n jälkeen oli 13% ja 
peräsuolisyöpäkuoleman riski 7%. Oireiden perusteella todettujen potilaiden 
kuolleisuus oli 34,9 tuhatta asukasta kohden ja seulonnasta löytyneiden vastaava 
luku oli 8,3. Eloonjäämisen ennuste oli oireiden perusteella diagnosoiduilla 
merkittävästi matalampi kuin seulontaan osallistuneilla, joilla 20-vuotisennuste oli 
jopa 94% verrattuna normaaliväestöön. Yli kaksi kolmasosaa kuolemista oli FAPiin 
liittyviä. Sporadisten desmoidikasvainpotilaiden riski familiaaliseen 
adenomatoottisen polypoosiin oli 4,8%. Kaikilla heillä oli selvä suolen tähystyksessä 
havaittava polypoosi. Lieviä vain geenimutaatiotestillä havaittavia AFAP tapauksia 
ei löytynyt. FAPiin liittyvät desmoidikasvaimet olivat suurempia. Ne sijaitsivat 
useammin vatsaontelon sisällä ja niitä on useammin useita. Sporadiset 
desmoidikasvainpotilaat olivat useammin naisia, kun taas FAPiin liittyvien 
desmoidikasvainpotilaiden keskuudessa sukupuolijakauma oli tasainen, ja potilaat 
olivat nuorempia. FAPiin liittyvien desmoidikasvainten hoito oli hankalampaa. 
Kasvaimen koko poisto oli usein mahdotonta, ja desmoidikasvaimeen liittyviä 
kuolemia oli FAPiin liittyvien desmoidien ryhmässä 14%. 
 
Päätelmät: IPAA ryhmässä ei ollut komplikaatioita enempää kuin IRA ryhmässä. 
Peräsuolisyövän riski säilyy kolektomian ja ileorektaaliliitoksen jälkeen, jonka 
vuoksi proktokolekomia ja IPAA on ensisijainen vaihtoehto potilailla, joilla on 
kohtalainen tai runsas polypoosi. Lisäksi pysyvän avanteen riski on suurempi, jos 
peräsuolen poisto tehdään myöhemmässä vaiheessa. Oireiden perusteella 
diagnosoitujen potilaiden elinajanennuste on merkittävästi huonompi kuin 
normaaliväestön. Tämän vuoksi kaikki FAP-potilaiden lähisukulaiset pitäisi saada 
seulonnan piiriin. Desmoidikasvainpotilaiden riski sairastua FAP:iin on kohonnut, 
ja siksi seulonta on suositeltavaa tälle potilasryhmälle. Ainoa poikkeus saattaa olla 
suoliston suhteen oireettomat potilaat, joilla desmoidikasvain sijaitsee vartalon 
ulkopuolisella alueella. FAP:iin liittyvien desmoidikasvainpotilaiden taudinkulku on 
monimutkaisempi, ja tämän vuoksi myös hoito on usein monimutkaisempaa. Mikäli 
mikroskooppisesti täydelliseen kasvaimen poistoon ei päästä, saattaa aktiivinen 
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Familial adenomatous polyposis (FAP) (MIM175000) is an inherited 
syndrome, which is characterized by the development of hundreds or 
thousands of adenomas in the colorectum (Bussey 1975). It is an autosomal 
dominant inherited disease. It refers to germline mutation of a gene called 
the adenomatous polyposis coli (APC). It is a rare syndrome with a frequency 
of about 1 per 10 000 inhabitants (Järvinen 1992, Bisgaard et al. 1994, Björk 
1999). The progression of polyps starts in early adulthood (Vasen et al. 
2008). There is a genotype-phenotype correlation with respect to the severity 
of colorectal polyposis. The patient has a virtually 100% risk of progression 
to colorectal cancer by the age of 35-40 years, if the condition is left 
untreated (Bussey 1975, Bisgaard et al. 1994).  
 
The first patient of the family, who is referred to as the proband, presents 
clinical symptoms of FAP. The symptoms are usually due to profound 
colorectal polyposis or colorectal cancer (Bussey 1975, Bülow 1991). Other 
symptoms or findings may also reveal FAP. These are for example, desmoid 
tumours in any part of the body or fundic gland polyps (FGP) in gastroscopy 
(Bülow 1991).  The family members of the proband are contacted to make an 
appointment (hereafter referred to as call-ups) for screening, which is 
hopefully before any symptoms arise. These call-ups that attend the first 
screening are on average 15-20 years younger than their symptomatic family 
members. Screening can be accomplished through endoscopy or by genetic 
testing. 
 
The first goal of the surveillance is preparing the patient for optimally timed 
prophylactic surgery. The main treatment method involves the excision of 
the colon or colon and rectum. There are many controversial aspects 
concerning such prophylactic surgery. For cases in which malignant lesion 
has already been diagnosed, the decision is easy: surgery must be done as 
soon as possible. In many situations, however, this is not a case. There might 
be a young healthy patient with no clear suspicion of malignancy, who ends 
up to an extensive operation. Moreover, the extent of the operation has to be 
decided. The choice can be between the excision of the colon and subsequent 
continuation of the surveillance of the rectum and the excision of the entire 
colorectum along with the ileoanal anastomosis o ileostomy. If the rectum is 
left in situ, the risk of rectal cancer remains. The estimated cumulative risk of 
rectal cancer after 40 years is reported to be up to 32% (Bülow et al. 2000). 
At present, proctocolectomy with ileal pouch-anal anastomosis (IPAA) is 
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considered as the treatment of choice for a majority of patients, but there are 
also arguments in favour of colectomy and ileorectal anastomosis (IRA) 
(Vasen et al. 2008, Campos 2014). 
 
The present effective prophylactic and cancer treatment of colorectal 
problems has led to a situation where other common premalignant or 
malignant conditions of FAP have come more important when evaluating the 
survival of FAP patients. Almost all FAP patients will eventually develop 
adenomas in the upper gastrointestinal tract and they also have a risk of 
progression into cancer (Bülow et al. 2004). Desmoid tumours are 
overexpressed among FAP patients. About 10-15% of FAP patients will have 
desmoid tumour during their lifetime (Nieuwenhuis et al. 2008, Campos et 
al. 2015). Desmoid tumours are not histologically malignant, but they may be 
as harmful as malignant tumours in the abdominal cavity. The treatment of 
widely growing desmoid tumours can be difficult and recurrences are 
commonplace. Nevertheless, desmoids are not malignant, and desmoid 
tumours are along with duodenal cancer the most common reason of deaths 
among FAP patients after the colorectal cancer (de Campos et al. 2010). 
 
The preventive effect of screening on colorectal deaths has been well 
documented and reported, but still there remain questions of the 
effectiveness of systematic screening in reducing the overall mortality 
(Heiskanen et al. 2000, Bülow 2003, Gibbons et al. 2011). Moreover, the 
optimal surgical procedure for every individual patient by taking into 
consideration the patient’s age, gender, and severity of polyposis and the 
location of the mutation as well as the patients’ own wishes still remains 




2. REVIEW OF THE LITERATURE 
2.1 Hereditary colorectal cancer syndromes 
There were about 3000 new colorectal cancer cases found in Finland in 2014. 
Colorectal cancer is the third most common cancer among men and the 
second most common cancer among women, and the incidence is rising. 
(Finnish cancer registry) About 30% of all colorectal cancer patients have a 
positive family history of colorectal cancer, which is indicative of a hereditary 
component. However, only 5% of colorectal cancer patients have a Mendelian 
inherited disorder with one specific gene mutation (Carballal et al. 2014, 
Brosens et al. 2015) (Table 1). 
Table 1 Hereditary colorectal cancer syndromes  




MLH1, MSH2, MSH6, PMS2 
or EpCAM  
Autosomal dominant 
Familial colorectal cancer 
type X 
Not known Not known 
 
FAP (also attenuated) 
(MIM175000) 
APC Autosomal dominant 
MUTYH-associated 
polyposis (MIM604933) 
MUTYH Autosomal recessive 
Peutz-Jeghers syndrome 
(MIM175200) 
STK11 Autosomal dominant 
Juvenile polyposis 
syndrome (MIM174900) 




GREM1 Autosomal dominant 
Serrated polyposis 
syndrome 
Not known Not known 
(Carballal et al. 2014, Brosens et al. 2015, OMIM database) 
 
The most common of the known Mendelian disorders is Lynch syndrome 
(Lynch et al. 2003). The lifetime risk for colorectal cancer ranges between 
10% and 74% (Brosens et al. 2015). Cancers are predominantly situated in 
the proximal colon and arise through the adenoma-carcinoma sequence; the 
sequence is much faster than among the sporadic cases. There are normally 
not many adenomas found in colonoscopy in contrast to the polyposis 
syndromes. Cancer is usually diagnosed about 10 years before sporadic cases 
(Giardiello et al. 2014). Lynch syndrome related colorectal cancers have an 
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improved survival among patients compared to those who have sporadic 
cancers at the same stage. Lynch syndrome is associated with several 
extracolonic cancer risks. The most common are endometrial cancer in 
women and urinary tract cancers. (Lynch et al. 2003, Brosens et al. 2015) 
 
There are families for which the criteria for Lynch syndrome are fulfilled, 
except that the mutation in genes involved is not found. This syndrome is 
called familial colorectal cancer type X. These patients tend to have colorectal 
cancer at older age and the colorectal cancers are less likely to be located in 
the right colon than the Lynch syndrome patients. Tumours are less likely to 
be mucinous and multiple. Otherwise the disease closely resembles that of 
the classic Lynch syndrome. (Valle et al. 2007) 
 
FAP is the second most common colorectal cancer syndrome and it is 
described in detail in this dissertation. It is also an autosomal dominant 
inherited syndrome that manifests hundreds or even thousands of 
adenomatous polyps throughout the colon and the rectum. The colorectal 
cancer risk for FAP patients is almost 100%, if left untreated (Bussey 1975, 
Bisgaard et al. 1994). There are fewer polyps and the colorectal cancer risk is 
about 70% among attenuated FAP patients (Burt et al. 2004).  
 
Human mutY homologue (MUTYH) -associated polyposis (MAP) is an 
autosomal recessive inherited syndrome. The phenotype is similar to that 
found in attenuated FAP (AFAP) patients, i.e. tens or hundreds of polyps are 
found throughout the colon and rectum. Polyposis is diagnosed later than in 
classical FAP. Polyps found among MAP patients can occur as adenomas or 
serrated polyps or both (Nielsen et al. 2011). The lifetime risk of colorectal 
cancer is around 80%. When CRC arises, the colectomy is indicated (Brosens 
et al. 2015).  
 
The hamartomatous polyposis syndromes are very rare. The best known of 
these are Peutz-Jeghers syndrome and juvenile polyposis syndrome. Peutz-
Jeghers syndrome is characterized by hamartomatous polyps throughout the 
gastrointestinal tract and typical mucocutaneous hyperpigmentation. In 
contrast, there are no skin findings among juvenile polyposis syndrome 
patients, only juvenile polyps found anywhere in the gastrointestinal tract. 
The risk of cancer at any site among Peutz-Jeghers syndrome can exceed 
90%. The risk of colon cancer is reported to be about 40%. Juvenile polyposis 
patients carry about the same colorectal cancer risk. Annual or biannual 
colonoscopy is recommended for both syndromes. There are also some other 
hamartomatous polyposis syndromes such as PTEN hamartoma tumour 
syndrome. (Gammon et al. 2009) 
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The latest of polyposis syndromes to be described is hyperplastic polyposis 
syndrome (also known as serrated polyposis syndrome). The diagnostic 
criteria of the syndrome is at least five hyperplastic polyps occurring 
proximal to the sigmoid colon or one hyperplastic polyp occurring proximal 
to sigmoid colon with a at least one first-degree relative with hyperplastic 
polyposis or more than 30 hyperplastic polyps anywhere in the colon (Jass et 
al. 2000). Although traditionally considered as benign polyps, hyperplastic 
polyposis syndrome patients carry a relatively high risk of colorectal cancer, 
which can possibly exceed 50% (Hyman et al. 2004). A convincing germ line 
gene mutation responsible of this syndrome has not been found at the time 
of writing this dissertation. 
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2.2 History, epidemiology and registries of FAP 
2.2.1 History 
Timeline of FAP (Bülow et al. 2006) 
 
1721: The first known description of polyps of the colon; Menzel reported a 
15 year-old boy who died of dysentery and had colonic polyps in autopsy. 
 
1881: Sklifasowski published the first known case report of adenomatous 
polyposis. He performed an operation where he removed large polyps 
through colostomy.  
 
1924: The first known proctocolectomy was performed by Coffey and 
Lockhart-Mummery discovered the hereditary factors of FAP. He established 
the first polyposis registry in St. Mark’s Hospital with Dr Cuthbert Dukes.  
 
1933: Nissen performed the first known proctocolectomy with straight 
ileoanal anastomosis in Leipzig.  
 
1939: Lochard-Mummery and Dukes reported the results of the prophylactic 
sigmoidoscopies performed on familial members of 10 families. They 
performed five prophylactic colectomies for them of which four succeeded. 
 
1951: Gardner described a condition afterwards named as Gardner’s 
syndrome. It included colorectal adenomas, desmoid tumours, bone tumours 
and soft cyst-like surface tumours. 
 
1956: Lochard-Mummery and others reviewed the surgical treatment 
recommendation for FAP. They recommended a colectomy and ileorectal 
anastomosis because the proctocolectomy and ileoanal anastomosis gave no 
good functional results. 
 
1975: Bussey published a thesis on the basis of the St. Mark’s polyposis 
registry. It described familial adenomatous polyposis in detail. 
 
1978: Park and colleagues introduced a new surgical procedure; 
proctocolectomy with mucosectomy and ileal pouch-anal anastomosis. 
 
1986: Herrera and others described an association of FAP and deletion in 
chromosome 5q, and Heald described stapled ileal pouch-anal 
anastomosis. 
 
1991: APC gene was characterised in detail in chromosome 5q21 (Groden et 
al. 1991, Joslyn et al. 1991, Kinzler et al. 1991, Nishisho et al. 1991). 
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2.2.2 Epidemiology/incidence 
The incidence of FAP was 1.58 per million in Finland during years 1986-90 
(Järvinen 1992).  The incidence of FAP in the Danish population was 1.9 per 
million inhabitants (1990-99), whereas in the Swedish population during the 
years 1977-96 it was approximately 0.9 (Björk 1999, Bülow 2003). The 
prevalence in the Finnish population during the years 1986-90 was 26.3 per 
million inhabitants. The prevalence in the Swedish population was 31.6 
(years 1992-96) per million inhabitants and in the Danish population it was 
31.9 per million (Järvinen 1992, Björk 1999, Bülow 2003). Men and women 
are equally affected (Bussey 1975). 
2.2.3 Registries 
The polyposis registry of St Mark’s hospital (London, UK) is the oldest 
registry. Dr Cuthbert Dukes and Mr J.P. Lockhart-Mummery founded the 
polyposis registry in 1924. The data of Finnish polyposis families have been 
collected since 1963 and enable continuing retrospective research from that 
date onwards.  Professor Heikki Järvinen in Finland established the official 
research registry for polyposis patients in 1984. The Finnish registry was 
founded for the purposes of research, but many patients and families 
belonging to the research registry have also been beneficially treated and 
informed during research projects. Several registry patients have also 
avoided cancer because of having correctly timed prophylactic treatment. 
When comparing the colorectal cancer incidence and colorectal cancer 
deaths among FAP patients in Finland and elsewhere before and after 
starting the registry there has been a significant reduction in both (Järvinen 
1992, Bülow 2003, Barrow et al. 2013). 
 
The proband i.e. prospositus for polyposis refers to the first patient that 
presents usually with the symptoms due to colonic polyposis. Upon diagnosis 
of a proband, the calling-up of relatives for screening has become standard 
procedure (Bussey 1975). In registries these patients are separated into their 
own groups for the evaluation of the effectiveness of screening and 
prophylactic treatment.  
2.3 Genetics of FAP 
2.3.1 APC gene 
The APC gene is identified as the gene responsible for familial adenomatous 
polyposis. Two different groups reported it independently; the group of Bert 
Vogelstein in Baltimore in collaboration with the group of Yusuke Nakamura 
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in Tokyo (Kinzler et al. 1991, Nishisho et al. 1991), and also by the group led 
by Ray White in Salt Lake City (Groden et al. 1991, Joslyn et al. 1991). The 
APC gene is situated in chromosome 5q21-q22. It is 139 kilobases in length 
and the longest coding transcript is 10.7 kilobases. The RefeSeq transcripts of 
APC gene contain variable number of exons (NM_000038: 16 exons, 
NM_001127510: 17 exons and NM_001127511: 14 exons). The longest 
transcript (NM_000038) of the gene encodes 2843 amino acids that form 
relatively large tumour suppressor protein called also APC. The APC protein 
contains binding sites for many other proteins including microtubules and 
the Wnt signaling pathway component called β-catenin (Goss et al. 2000, 
Aoki et al. 2007). A predominant tumour suppressor function of the APC 
protein is to control β-catenin levels in the cytoplasm (Kemler 1993). If the 
mutation occurs and the APC protein is truncated, the binding sites no longer 
exist and the overexpression of β-catenin will occur (Aoki et al. 2007).  
 
According to the Knudson’s two hit hypothesis (Figure 1) germline mutation 
in one copy of APC gene itself is insufficient for carcinogenesis to occur, but 
when the second copy mutates the development of colorectal cancer can start 
(Knudson 1971). In sporadic cancers a mutation in both copies must occur in 
every cell, but the APC gene mutation has been shown to be involved in 
sporadic colorectal cancer carcinogenesis, too (Powell et al. 1992). Mutation 
of the APC gene is the first step in the development of colorectal cancer via 
adenoma-carcinoma-sequence in FAP patients in addition to the sporadic 
colorectal cancer patients.  
 
 
Figure 1 Knudson’s two hit hypothesis of oncogenesis, adapted from Jozwiac J et al. 2008. 
Possible mechanisms of disease development in tuberous sclerosis, The Lancet 
Oncology 9:73-79, 2008 by permission from Elsevier Ltd.  
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More than 1600 germline mutations of APC have been reported (HGMD 
database). Of these 289 have reported to be pathogenic or likely pathogenic 
in ClinVar Database, which is known to contain relatively reliable variant 
classifications (clinvar database). Truncating mutations leads to a truncated 
protein due to premature termination of messenger RNA translation. 
Truncating mutations are the most common genetic defects in FAP. 
Truncations are either consequence from a nonsense mutation (direct stop 
codon, 32%), or small insertion or deletion (42%) leading to altered reading 
frame ‘frameshift’ with a premature stop codon in the downstream coding 
sequence. Moreover, splicing mutations are also frequent (8.3%) and some 
missense mutations have been described (Leoz et al. 2015, clinvar database). 
However, only three missense variants are uniformly classified as pathogenic 
or likely pathogenic in ClinVar as others have conflicting interpretations. 
Two out of these three missense variants (c.423G>T, p.(Arg141Ser), 
c.1548G>C, p.(Lys516Asn)) are located in the coding region next to 
consensus splice site and have confirmed to have effect on splicing. 
 
The mutation site has a high impact on the phenotype expressed. If the 
mutation occurs in the middle of the APC gene, between codons 1250 and 
1464, phenotype is usually more severe than a mutation in the border region 
of the gene (Nagase et al. 1992). The most frequent APC pathogenic mutation 
is located at codon 1309 (NM_000038.5: c.3924delA p.(Glu1309Lysfs*12), 
c.3925_3926delGA, p.(Glu1309Lysfs*5), c.3927_3931delAAAGA 
p.(Glu1309Aspfs), c.3925_3928delGAAA p.(Glu1309Argfs), c.3925G>T 
p.(Glu1309*)) (Leiden Open Variation database).  
 
The APC germline mutations achieve almost 100% penetrance (Fearnhead et 
al 2001). Of the germline mutations the proportion of de novo mutations is 
reported to vary between 11-25% (Bisgaard et al. 1994, Björk et al. 1999). 
2.3.2 Adenoma-carcinoma sequence in FAP 
Genetics of colorectal cancer has been widely investigated. At least three 
different genetic pathways have been reported; adenoma-carcinoma 
sequence is the best studied. The APC gene mutation via the Wnt signaling 
pathway is responsible for the first step of this process (Figure 2). The 
mutation in the APC gene causes the formation of hundreds or thousands of 
primarily benign polyps. These polyps can undergo malignant progression, 
but this also requires a series of other mutations to happen in the polyp. 
There are many adenomas, however, and at least some will progress to 
cancer (Kinzler et al. 1996).  




Figure 2 Adenoma carcinoma sequence, published with the permission obtained from the 
syscol website and adapted from Davies RJ, et al. Colorectal cancer screening: 
prospects for molecular stool analysis, Nature Review Cancer 5:199-209, 2005 by 
permission from Macmillan Publishers Ltd.  
2.3.3 Genotype-phenotype correlation in polyposis 
The mutation on different parts of the APC gene leads to different degrees of 
polyposis (Figure 3). A mutation between codons 1250 and 1464 leads to 
severe polyposis (>5000 colorectal polyps), and mutations in the 1309 codon 
are especially associated with severe polyposis with early onset of symptoms 
(Caspari et al. 1994). Mutations in attenuated polyposis has been reported to 
be situated in either the terminus of the APC gene, codons <157 or > 1595 or 
in the alternatively spliced site of exon 9 (codons 312-412) (Nieuwenhuis et 
al. 2007). Classical or intermediate polyposis is found among patients with 
mutations between codons 157 and 1595, excluding the areas of severe 
polyposis and attenuated polyposis in the middle of this region. In 
individuals of which the mutation is located between 976 and 1067 have 
reported to have a fourfold risk for duodenal adenomas (Bertario et al. 
2003).   
 
 
Figure 3 Severity of FAP according to codon in APC (nm 00038.5) (modified from 
Nieuwenhuis et al. 2011, Leoz et al. 2015) 
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2.3.4 Genotype-phenotype correlation in other manifestations 
Desmoid disease has been linked to mutations near to the 3'-end of the gene, 
especially beyond codon 1444 (Bertario et al. 2001, Lefevre et al. 2008). 
Congenital hypertrophy of the retinal pigment epithelium is associated with 
codons between 311-1444 (Davies et al. 1995). Papillary thyroid carcinoma 
has been reported to be associated to mutations near to the 3'-end of the 
gene (Groen et al. 2008). Hepatoblastoma is associated for a quite wide 
range of mutations between 141 and 1751 codons (Hirschman et al. 2005, 
Groen et al. 2008). Osteomas are associated to mutations found in codons 
767 to 1578 (Groen et al. 2008). Brain tumours, mostly those of 
medulloblastoma, are associated with mutations between codons 686–1217 
(Attard et al. 2007). The genotype-phenotype correlation of extra-intestinal 
manifestations is illustrated in figure below (Figure 4). 
 
Figure 4 Extra intestinal manifestations according to affected codon in APC (nm 00038.5) 
(modified from Groen et al. 2008, Leoz et al. 2015). 
2.4 Classification and histology of FAP 
2.4.1 FAP 
Classical FAP is defined as having over 100 adenomas presenting throughout 
the colorectum. The total number of polyps has been reported to vary from 
about 100 to 5000, the average is around 1000, and the density of polyps 
from 0.15 to 3 per square cm (Bussey 1975). Adenomas usually appear in 
adolescence. The patient’s mean age at colonic polyp occurrence is 15.9 years 
(Petersen et al. 1991). 
2.4.2 AFAP 
A subset of polyposis patients expresses a milder phenotype than the 
classical FAP. This phenotype is termed attenuated familial adenomatous 
polyposis (AFAP). Typically the AFAP patient has fewer than 100 polyps in 
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the colorectal region, which are distributed dominantly on the right side of 
the colon. Rectal sparing of adenomas has also been reported (Lynch et al. 
1995). Patients with this subtype have a delay in the onset of adenomatosis 
and a delay in the onset of colorectal cancer too (Knudsen et al. 2003). 
Mutations are situated at the either 3'- or 5'- end of the APC gene or in exon 9 
(Soravia et al. 1998). The upper gastrointestinal manifestations such as FGPs 
and duodenal adenomas are usually found in AFAP as they are in classic 
FAP. In general, AFAP has been reported to be associated with a lower 
desmoid tumour risk. However, disease associating variants locating in 
specific region at the 3'-end of the APC gene associate to higher risk for 
desmoid tumours (Bertario et al. 2001). 
2.4.3 Histology of FAP polyps 
The polyps found in FAP are adenomatous polyps. They are pre-neoplastic 
polyps that consist of an overgrowth of hyperplastic intestinal mucus 
secreting epithelium (Bussey 1975). There are microscopic adenomas in FAP 
patients and these include single dysplastic crypts in normal looking mucosa 
around the polyps. The single dysplastic crypts, also called unicryptal 
adenomas, are pathognomonic for FAP (Novelli 2015). Polyps can be tubular 
adenomas, villous adenomas or intermediate tubulo-villous adenomas. Most 
of the polyps are under 0.5 cm in diameter and spread as a mat throughout 
the colon. The greater the diameter, the bigger is the risk of malignant 
histology. The histopathology of adenomas and adenocarcinomas in FAP are 
the same as the corresponding sporadic counterparts (Bussey 1975). 
2.5 Screening and diagnostics of FAP 
2.5.1 Clinical presentation 
Patients with FAP nowadays present mostly without symptoms. Many 
patients are found because of a screening protocol or through the 
investigation of some other unrelated complaint. Some patients are referred 
for testing because of extracolonic manifestations such as supernumerary 
teeth, osteomas, desmoid tumour or congenital hypertrophy of the retinal 
pigment epithelium. If symptoms of polyposis are actually present, they may 
include bleeding, change in bowel habits, and abdominal pain (Yeo et al. 
2013). The penetrance rate of the colonic polyposis disease for inherited 
cases is estimated to be close to 100% by the age of 40 years (Bisgaard et al. 
1994). Over 70% of adenomas in classical FAP occur on the left side of the 




Figure 5 A) Opened proctocolectomy specimen of a patient with a severe polyposis, B) 
Endoscopic view from the colon of the FAP patient (picture creator: Miguel 
Rodrigues-Bigas, MD Anderson Cancer Center by permission from National 
Cancer Institute) C) CHRPE D) Opened gastrectomy specimen, gastric polyposis 
E) Endoscopy view, duodenal adenomatosis F) CT scan section of intra-
abdominal desmoid tumour (pictures A, C-F from Heikki Järvinen and Anna 
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2.5.2 Endoscopy 
A person with 10 or more adenomas in the colorectum should raise suspicion 
of FAP. Classical FAP can be easily diagnosed by sigmoidoscopy in early 
adulthood. Biannual endoscopic screening of children at risk should begin as 
teenagers or at any age in the presence of FAP-related symptoms (Barnard 
2009). The finding is usually obvious with hundreds or even thousands of 
polyps throughout the distal colon. In cases of milder phenotype, the 
diagnosis with sigmoidoscopy alone in not always clear. Total colonoscopy is 
recommended when there is a suspicion of AFAP as the polyps are often 
located on the right site of colon (Nielsen et al. 2007). After the diagnosis has 
been made, the annual screening for high risk adenomas should be continued 
until prophylactic surgery has taken place. Under colonoscopy the size of the 
biggest polyps should be recorded and the approximate polyp count and their 
distribution around colorectal area should also registered and several 
biopsies should be taken. The histology of the adenomatous polyps do not 
differ from that of the sporadic adenomas (Syngal et al. 2015). 
 
The first upper endoscopy should be performed at the age of 30 at the latest 
or earlier if patients have upper GI symptoms.  Duodenal cancer before age 
30 is extremely rare (Brosens et al. 2005). The interval between the upper 
endoscopy is determined according to Spigelman stage (Vasen et al. 1997). 
2.5.3 Genetic counseling and mutation testing 
The patient must receive genetic counseling along with the mutation testing. 
The pretesting counseling session should include a review of patients’ 
medical history, an evaluation of whether the genetic testing is appropriate, 
collecting the pedigree data, education of the patient and family about the 
medical aspects of potential disease, the patterns of inheritance, and the 
recommended screening and follow up guidelines. After a comprehensive 
and detailed first counseling has been carried out, the informed signed 
consent can be signed by the patient and blood draw for genetic testing can 
be taken. (Giardiello et al. 1997, Wong et al. 2001) If there is already a known 
mutation within a family, the genetic testing for that particular mutation can 
be performed. Some suggest that genetic screening should be performed 
between the ages of 10 to 12 years (Barnard 2009). Sporadic adenoma 
patients with over 10 adenomas in the colorectal area should be offered 
genetic testing. If a patient is the first individual in the family attending 
genetic testing, the full sequencing of the coding region of the APC gene is 
performed. Over 85% of all mutations can be found with classic sequencing. 
The other 10-15% of mutations are gross deletions and duplications, which 
can be detected with multiplex ligation-dependent probe amplification 
(MLPA) or other methods (Leoz et al. 2015). At present, the direct 
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sequencing is first done and if nothing is found, then screening is continued 
with MLPA. If the APC mutation is not found with MLPA either, and the 
clinical phenotype is similar to AFAP, then the MUTYH mutation screening 
should be done. Lately multigene panels have become available that allows 
detection of both sequence variants and deletions/duplications from the 
genes in one assay (Hedge et al. 2013).  When the mutation is found all the 
information of the follow-up and treatment options are given. The patient is 
also advised to inform the family members about the risk of FAP. (Wong et 
al. 2001) First-degree relatives carry a 50% of risk of FAP. It remains the 
patient’s responsibility to inform close family members. There are also a 
proportion of patients with undisputed FAP upon endoscopy, but no 
mutation can be found by gene mutation testing. The APC mutations were 
found in 80% of individuals with more than 1000 adenomas, 56% in those 
with 100–999 adenomas, 10% in those with 20-99 adenomas and 5% in 
those with 10-19 adenomas (Nielsen et al. 2007). Even though a known APC 
mutation cannot be found, and the patient fulfills the other diagnostic 
criteria for FAP based on the endoscopy findings, then regular surveillance 
and prophylactic surgery should still be undertaken. The colonoscopy 
screening should also be offered to first degree relatives.  
2.6 Treatment of colonic polyposis 
All patients with FAP are recommended to undergo prophylactic colonic or 
colorectal surgery because of the almost 100% risk of colorectal cancer. At 
present there are two different options: colectomy with ileorectal 
anastomosis (IRA) and proctocolectomy with ileal pouch-anal anastomosis 
(IPAA) (Figure 6). The traditional method of proctocolectomy and 
permanent Brooke’s ileostomy is not widely used nowadays, because of the 
disadvantages related to permanent stoma formation. It is however 
sometimes used for patients with low rectal cancer, or sphincter dysfunction. 
In rare cases, Brooke’s ileostomy is used when it becomes evident during the 
IPAA operation that the ileal pouch cannot be pulled down to the anus 
because of mesenteric desmoid or because of too short and fatty mesentery 
(Campos 2014). When the patient has severe co-morbidities, IPAA is not 
always performed, even if it were technically possible. In IRA procedure 
abdominal colectomy is performed with the anastomosis between the ileum 
and the rectum. The procedure of IPAA entails the colon and rectum being 
removed and the pouch is formed from the terminal ileum. The pouch is then 
attached to the anal canal after the mucosectomy of the anal stump. Parks 
and Nicholls introduced the proctocolectomy and hand-sewn anastomosis 
with the S-shaped pouch in 1978 (Parks et al. 1978) and two years later 
Utsunomiya described a simpler pouch in a J configuration (Utsunomiya et 
al. 1980). This hand-sewn anastomosis and J construction of the pouch is 
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still in use as a standard technique. Heald described an alternative technique 
with a stapled anastomosis between ileal pouch and the anus (Heald et al. 
1986). A short segment of the rectal mucosa is left behind in the stapled 
technique. Diverting temporary ileostomy was originally routinely performed 
in connection with the IPAA and nowadays some centers also use it as a 
standard, and some other only when the patient has some complication risk-
increasing factor such as immunodeficiency. (Weston-Petrides et al. 2008) 
 
 
Figure 6 Illustration of colectomy and proctocolectomy procedures. Adapted from M’Koma 
AE, Wise, P.E., Muldoon, R.L. et al. Int J Colorectal Dis (2007) 22: 1143-63, 2007 
by permission from Springer.  by permission from Macmillan Publishers Ltd 
 
When the patient does not have invasive cancer or severe dysplasia in 
preoperative biopsies and the operation is performed as a prophylaxis, the 
colonic dissection is usually performed close to the colonic wall. The rectal 
dissection should also be performed away from the presacral fascia (within 
the mesorectum) in order to avoid damage to the pelvic autonomic nerves. 
The total mesorectal excision (TME) technique is used, when the patient has 
a cancer or a premalignant lesion of the rectum (Kartheuser et al. 2006). The 
TME technique is also preferable for obese males with a narrow pelvis to help 
the pouch to fit down into the lower pelvis. Furthermore the colon is 
mobilized in an oncologically safe manner in the case of colon cancer. 
 
In general, laparoscopic colorectal surgery has shown to be as safe as open 
colorectal surgery (Fichera et al. 2009, Jayne et al. 2010). There is also a 
trend among FAP patients towards laparoscopic approach.  Comparing 
laparoscopic and open IPAA among FAP or ulcerative colitis patients there is 
no difference in mortality or morbidity between the groups (Polle et al. 
2008). A possible reduction of post-operative desmoid formation related to 
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laparoscopic colectomies has also been shown (Vitellaro et al. 2014). 
Although that study had substantial limitations; the laparoscopic group was 
small and the follow-up time was significantly shorter for the laparoscopic 
than for the open groups (Vitellaro et al. 2014). Laparoscopic IPAA on the 
whole seems not be inferior to the open technique, but no major advantages 
for laparoscopic IPAA have been reported yet. 
2.6.1 Timing of surgery 
Timing of the prophylactic surgery is planned with due consideration with 
the patient’s wishes, clinical characteristics of the polyposis and the location 
of mutation. Prophylactic surgery is usually performed between the ages 15 
and 25. The risk of carcinoma before the age of 20 years is 1% for the whole 
FAP population (Vasen et al. 2008).  However, those families that manifest a 
strong penetrance, malignant or premalignant lesions are not infrequently 
seen. There are several conditions when the postponement of surgery must 
be avoided. For patients having adenoma related symptoms, such as 
diarrhoea or bleeding, or those that have high-grade dysplasia or profuse 
adenomatosis or large adenomas, the surgery must not be postponed. The 
symptomatic polyposis is more likely to be severe and the risk of already 
existing carcinoma is also higher (Bülow 2003). If there is a verified or 
suspected cancer, surgery must be organized as soon as possible and in an 
oncologically safe manner. If the mutation site is in a high risk area for 
profuse polyposis (i.e. between codons 1250-1464) it is also an indication not 
to delay surgery (Campos 2014).  
 
In the case of mild polyposis such as in AFAP at colonoscopy or on the basis 
of family history or genotype, the postponing of the surgery might be 
justified (Campos 2014). If the patient is asymptomatic, surgery can be 
postponed, but annual surveillance must be organized and the patient must 
be compliant with that surveillance (Campos 2014). It has also been 
proposed that a high-risk for desmoid tumour because of the mutation 
situation and/or family history could be a reason for postponing the surgery 
(Sturt et al. 2006). 
2.6.2 Indications for IRA 
When making the choice between IPAA and IRA, the patient’s age, clinical 
condition and personal preferences must be taken account. Proctocolectomy 
followed by IPAA is nowadays the surgery of choice for classical FAP 
(Kartheuser et al. 1996). It restores gastrointestinal continuity and transanal 
defecation, and avoids a permanent stoma. Its major advantage is that the 
total proctocolectomy is accomplished in one session, and so the risk of 
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colorectal cancer is eliminated. There are still many unquestionable 
advantages in colectomy and IRA. Colectomy and IRA is easy to perform and 
it has relatively good functional results. Moreover, the secondary 
proctectomy and IPAA still remains an option after IRA for most patients. 
However, the risk of rectal cancer remains after IRA, and that risk is 
substantial (Iwama et al. 1994, Bülow et al. 2000, Aziz et al. 2006).  
 
Colectomy and IRA is generally recommended for a patient with mild FAP as 
diagnosed by endoscopy or for AFAP by family history, endoscopy or 
mutation testing.  If the rectum is reasonably clear of polyps, it can be left in 
situ. It has been suggested that there should be fewer than five polyps in the 
rectum, which are removable endoscopically. No adenomas with high grade 
dysplasia should be found in the rectum (Church et al. 2001). Further, the 
patient with the rectum left in situ should have good compliance for future 
annual rectal endoscopy, which is mandatory for all IRA operated FAP 
patients. Among young females the preservation of fecundity is important. It 
had previously been considered that fecundity after IPAA was reduced 
among FAP patients, but not after IRA (Olsen et al. 2003). However, a more 
recent study demonstrated there was no difference in fertility after IRA, 
IPAA, or proctocolectomy with ileostomy (Nieuwenhuis et al. 2010). The 
choice of operation type for patients with a high risk for desmoid disease due 
to family history or APC mutation site has recently been under debate. It has 
been suggested that after IRA a secondary proctectomy may be technically 
impossible because of the developing desmoid. Furthermore, if the 
proctectomy were actually possible, then the IPAA may still be prevented by 
a shortened and thickened mesentery because of an existing desmoid tumour 
(Vasen et al. 2008). Another study reported that the desmoid tumour 
prevented only one of 67 proctectomies, whereas 12% of the restorative 
proctectomies with ileal pouches did not succeed because of desmoid tumour 
(Church et al. 2014). No difference in desmoid formation after different 
procedures has been shown (Burgess et al. 2011). 
2.6.3 Complications of surgery 
The IPAA is a technically demanding procedure. It is associated with low 
mortality rates, but it is frequently accompanied by early and late 
complications. The IRA procedure also carries a risk of early and late 
complications even if it is technically easier to perform. The most frequent 
early complications include haemorrhage, surgical site infection, which can 
vary from mild wound infection to intra-abdominal septic condition such as 
leakage or abscess, and post-operative bowel obstruction. The overall 
complication rate after IRA has been reported to be around 20% and after 
IPAA around 27% (Madden et al. 1991, Ambroze et al. 1992, Tonelli et al. 
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1997, Duijvendijk et al. 1999, Soravia et al. 1999, Björk et al. 2001, Günther et 
al. 2003, von Roon et al. 2008, Campos et al. 2009, Bülow et al. 2013, Fazio 
et al. 2013). The complication prevalences from the different studies are 
presented in Table 2. A large meta-analysis that compared IPAA and IRA 
reported no significant difference in early post-operative complications 
between either procedure. However, increased 30 day reoperation rate was 
associated with IPAA; 23.4 vs. 11.6% (Aziz et al. 2006). 
 
The prevalences of long-term adverse events and functional outcome are 
presented in Table 3. The rate of late complications after IPAA in general 
seems to be higher (Duijvendijk et al. 1999).  The functional outcomes of IRA 
had better results in terms of reduced bowel movement, reduced need for 
night defecations, and reduced use of incontinence pads. There was more 
faecal urgency in the IRA group however. No difference was found between 
IRA and IPAA groups in the terms of bowel frequency at night, daytime 
incontinence, and need for antidiarrhoeal medication. (Aziz et al. 2006) 
 
Overall short and long-term complication rates between primary and 
secondary IPAA have been reported to be at the same level (Penna et al. 
1993, von Roon et al. 2008, Bülow et al. 2013). The overall IPAA failure rate 
reported ranged between 4% and 10% (Lepistö et al. 2002, Fazio et al. 2003, 
Lovegrove al. 2006, Hahnloser et al. 2007, von Roon et al. 2008, Bülow et al. 
2013). 
 
There is no difference observed in quality of life between IRA and IPAA 
operations, but in both groups the quality of life was inferior to the general 
population (van Duijvendijk et al. 2000, Aziz et al. 2006). When quality of 
life was compared in some other studies for FAP patients who underwent 
IPAA to normal population, there was no difference detected. There was 
however, a difference in the gastrointestinal quality of life in these studies. 
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2.6.4 Risk of rectal cancer and secondary proctectomy after IRA 
The risk of rectal cancer after IRA remains. Several risk factors for rectal 
cancer have been presented, these include: high density of colorectal polyps 
500 or more, rectal polyp count over 20, patient’s older age, or patients’ age 
younger than 25 at the time of surgery, the length of the retained rectal 
stump, colon cancer at the initial operation and inadequate rectal 
surveillance (Gingold et al. 1981, De Cosse et al. 1992, Bertario et al. 2000, 
Sinha et al. 2010). More recently, a high risk site of APC mutation have been 
added to this list of risk factors (Bertario et al. 2000, Sinha et al. 2010). The 
rectum must be annually surveyed by endoscopy, and despite the annual 
endoscopy some polyps might still develop into cancer during the 
surveillance interval. The overall rectal cancer risk after colectomy and IRA is 
reported to be 6-14% (Iwama et al. 1994, Heiskanen et al. 1997, Bülow et al. 
2000, Aziz et al. 2006). The risk increases with the lengthening follow-up 
time. The long-term risk estimates vary and reach up to 24% at 15 years and 
32% at 40 years after IRA (Iwama et al. 1994, Heiskanen et al. 1997, Bülow et 
al. 2000): these numbers are partly from the pre-IPAA era. During the IPAA 
era, the rectal cancer risk of IRA procedure has diminished perhaps mostly 
because of right patient selection for the both operations (Church et al. 
2003). The cumulative 5-year survival for rectal cancer after colectomy and 
IRA is 60% (Bülow et al. 2000). Even if the rectal cancer risk is the major 
indication for the secondary proctectomy, not all patients have cancer at the 
actual time of surgery. Many patients have a worsening rectal polyposis, 
which makes endoscopic surveillance difficult and unreliable. Therefore, the 
secondary proctectomy rates are much higher than actual cancer numbers. 
The risk of secondary proctectomy is reported to be around 30% and the 
cancer detected in secondary proctectomy specimen is about 30%, 
respectively (Björk et al. 2000, Sinha et al. 2010). The estimated cumulative 
risk of secondary proctectomy, including the pre-IPAA era, is estimated to be 
around 70% over 30 to 40 years (Heiskanen et al. 1997, Bülow et al. 2000). 
The secondary proctectomy during the IPAA era, which began in 1992 
accounts for only a little over 10% of the IRA patients, and the cumulative 
risk at 10 years is 16% (Bülow et al. 2008). The figures with a very long 
follow-up after the introduction of IPAA are therefore still lacking.   
 
If the secondary proctectomy has to be carried out, the aim is to preserve the 
anus and to perform secondary ileal pouch-anal anastomosis. The secondary 
IPAA may be a technically more challenging operation due to the adhesions 
and sometimes, mesenteric desmoid occurrence within the operating area 
(Bülow et al. 2000). Mesenteric desmoid sometimes prevents the 
reconstruction of ileal reservoir and ileoanal anastomosis.  The 
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intraoperative technical difficulties that prevent ileal-pouch formation affect 
8-10% of cases (Penna et al. 1993, von Roon et al 2008). It has not been 
congruently shown if there are more complications in secondary IPAA 
(Bülow et al. 2000, Björk et al. 2001). 
 
If the secondary IPAA procedure is successful, then the long term outcome is 
as good as with the primary IPAA. Secondary IPAA failures occur at the same 
frequency as in primary IPAA (Bülow et al. 2013).  
2.6.5 Surveillance after colorectal surgery 
All the patients need surveillance after prophylactic colorectal surgery. The 
rectal cancer risk is such that an annual endoscopy of the rectal stump is 
indicated for patients, who had undergone IRA. Rectal cancer will arise 
amongst a certain portion of patients in spite of annual surveillance, but the 
purpose of surveillance is to detect precancerous lesions in advance or at 
least cancer at its earliest stage so that curative treatment is still feasible and 
available. 
 
The ileal pouch created during IPAA procedure is prone to adenoma 
formation (Beart et al. 1982). The incidence of adenomas among FAP 
patients in the ileal pouch varies from 7% to 74% depending on the study. 
The cumulative risk ranges are 7% to 16% after 5 years, 35% to 42% after 10 
years, and 75% after 15 years (Friederich et al. 2008, Tajika et al. 2013). 
Although the rate of adenomas has shown to be quite high, the cancer risk is 
still low. The 10 year-cumulative-risk of pouch cancer was no more than 1% 
(Friederich et al. 2008). Nevertheless, regular pouch surveillance is advised 
for all FAP patients with IPAA (Mc Launghlin et al. 2009). 
 
The surveillance of upper gastrointestinal polyps remains unchanged after 
colectomy (Spigelman et al. 1989). 
2.6.6 Medical treatment 
Non-steroidal anti-inflammatory drugs (NSAID) have been reported to 
diminish the colorectal polyp formation among FAP patients (Steinbach et al. 
2000).  The only effective prevention of colorectal cancer is by surgery, but 
there are, however, some special cases, when the chemoprevention over a 
limited period of time could be an appropriate choice. In some patients a 
large intra-abdominal desmoid tumour may prevent the secondary 
proctectomy after colectomy and IRA and in such a case the COX-2 inhibitor, 
celecoxib, with the annual endoscopic removal of rectal polyps will be the 
only treatment option. The European Society for Medical Oncology (ESMO) 
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guidelines for the year 2013 states that NSAIDs can be used as adjuvant 
treatments when adenoma recurrence is detected after surgery (Balmana et 
al. 2013). Normal dosage is 200 milligrams of celecoxib twice a day. The 
NSAIDs, sulindac and celecoxib both have shown to reduce the adenoma 
burden in the rectum after IRA, and the celecoxib possibly reduces small 
duodenal adenomas as well (Kim et al. 2011).  Notwithstanding the treatment 
by NSAID medication may cause polyp regression, no reduction in the 
progression to adenocarcinoma has been shown (Kim et al. 2011). 
2.6.7 Endoscopic treatment 
Endoscopic surveillance with polyp removal has been used to prevent rectal 
cancer after colectomy and ileorectal anastomosis. The upper gastrointestinal 
polyps are often removed via endoscopy. Sometimes very mild cases of AFAP 
can also be considered to be managed by endoscopic polyp removal only. 
Endoscopy may also help to postpone upcoming surgery, if the patient is 
reluctant to have the prophylactic operation (Ishikawa et al. 2015). 
2.7  Extra-colonic manifestations of FAP 
Different manifestations of FAP are presented in schematic figure (Figure 7). 
 
 
Figure 7 Manifestations of FAP, intestinal manifestations are coloured in orange and 
extraintestinal manifestations in black adapted from Boixadera Espax H et al. 
Radiologic manifestations of Gardner's syndrome (C-2191) EPOSTM poster 
presented at ECR 2011 by permission from the European Society of Radiology. 
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2.7.1 Duodenal adenomas and other intestinal adenomas 
The duodenum is the second most commonly affected site in FAP (Sarre et 
al. 1987). The lifetime risk of duodenal adenomas for FAP patients has been 
reported to be virtually 100% (Heiskanen et al. 1999, Bülow et al. 2004). 
Duodenal adenocarcinoma is the second or third most common cause of 
death together with desmoid tumours. Cumulative duodenal cancer risk has 
been reported to be between 5% and 10% at the age of 60 years (Björk et al. 
2001, Bülow et al. 2004, Lepistö et al. 2009). Even though the clinically 
relevant adenomas mostly occur in the duodenum, adenomas are also 
detected more distal to duodenum in small intestine (Alderlieste et al. 2013). 
The severity of duodenal polyposis has reported to be a predictor for 
detecting adenomas in jejunum and ileum, but advanced lesions are found 
rarely and only in jejunum (Ruys et al. 2010, Alderlieste et al. 2013). The 
polyp burden is reported to be largest in the proximal jejunum. Nevertheless, 
routine endoscopy beyond duodenum is not recommended. (Alderlieste et al. 
2013)  
 
Duodenal adenomatosis must be routinely followed-up among all FAP 
patients. Recommendations regarding the initiation of upper gastrointestinal 
tract endoscopies vary. Some groups suggest screening starting at the time of 
diagnosis and others at the ages of 25-30 years (Morburgo et al. 2004, 
Brosens et al. 2005, Vasen et al. 2008). Nevertheless, there is no rush to 
perform duodenoscopy in young FAP patients, because duodenal cancer is 
very rare before 30 years of age (Brosens et al. 2005). It is however 
recommended to perform duodenoscopy before prophylactic colectomy. The 
interval of the endoscopies is defined according to duodenal polyposis 
severity, which is defined with the Spigelman classification (Table 4 & 5) 
(Spigelman et al. 1989).  
Table 4  Spigelman classification for duodenal polyps 
POINTS 1 2 3 
No of polyps 1-4 5-20 >20 
Size of polyp (mm) 1-4 5-10 >10 
Histology Tubular Tubulovillous Villous 
Dysplasia Mild Moderate Severe 
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Table 5 The risk of duodenal cancer according to Spigelman stage. 
SPIGELMAN SCORE STAGE Duodenal cancer risk (%) 10 
years (Groves et al. 2002) 
1-4 I 0 
5-6 II 2.3 
7-8 III 2.4 
9-12 IV 36.4 
 
 
The National Comprehensive Cancer Network’s (NCCN) recommendation for 
surveillance according to stage is: stage 0 every 4 years, stage I from 2 to 3 
years, stage II from 1 to 3 years, stage III from 6 to 12 months, stage IV; no 
more surveillance, surgery (NCCN database). Duodenal adenomas can be 
treated primarily endoscopically. Large duodenal polyps can often be 
removed by snare excision or by endoscopic submucosal dissection technique 
under anesthesia. Duodenal adenomas are prone to recur after endoscopic 
removal. Celecoxib is used for Spigelman II and III polyposis for restraining 
the polyp formation (Groves et al. 2002). Surgical treatment options for 
duodenal adenomas are local excisions through duodenotomy, pancreas 
saving duodenectomy and pancreaticoduodenectomy. After duodenotomy 
the local recurrence rate is high, 43% in 10 years of follow-up (Farnell et al. 
2000, Lepistö et al. 2009). Pylorus saving pancreaticoduodenectomy is 
recommended usually for stage III-IV duodenal adenomatosis and for 
patients with high grade dysplasia. With this treatment regimen, the 
occurrence of duodenal cancer was limited to 4.7% and there were no deaths 
due to duodenal cancer (Lepistö et al. 2009).   
2.7.2 Fundic gland polyps, gastric adenomas and pyloric gland 
adenomas 
FGPs are the most common polyps in the stomachs of FAP patients. FAP-
associated FGPs are reported for up to 88% of all FAP patients (Bianchi et al. 
2008, Lepistö et al. 2009). Histopathologically they are fundic glands, which 
are irregularly budded and cystically dilated in otherwise normal mucosa 
(Abraham et al. 2000). They are usually considered to be non-neoplastic; 
hamartomatous or hyperplastic lesions, although about 40% of FGPs have 
reported to have dysplasia, usually of low grade (Bertoni et al. 1999, Bianchi 
et al. 2008). High grade dysplasia is rare, and occurs usually in large (over 
one centimeter diameter) FGPs. Prophylactic gastrectomy should be 
considered in cases of repeated high grade dysplasia found in biopsies 
(Bianchi et al. 2008).  
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The risk of gastric adenomas is also increased among FAP patients. The 
incidence of adenomas has reported to be around 10% among the western 
FAP population. A transformation to gastric cancer is still uncommon (Biachi 
et al. 2008, Ngamruengphong et al. 2014). 
 
Recently, a newly found entity, the pyloric gland adenomas, has been 
reported to be more common among FAP patients. Pyloric gland adenomas 
have been reported to occur in 6% of FAP patients whom undergo upper 
gastrointestinal tract endoscopy (Wood et al. 2014). 
2.7.3 Desmoid tumours 
Desmoid tumours are histologically benign mesenchymal tumours that arise 
from fibroblasts or myofibroblasts, which can be located in any part of the 
body. They may act aggressively when growing fast in inappropriate places. 
Desmoid tumours do not metastasize, however. The name aggressive 
fibromatosis is also used (Shields et al. 2001). Among FAP patients there is 
more than 800-fold the risk of desmoid tumour formation that in the general 
population (Nieuwenhuis et al. 2011). Other risk factors for desmoid tumours 
are pregnancy and previous trauma, either surgical or incidental for a 
desmoid area (Reitamo et al. 1986).  
 
The median frequency of desmoid tumours among FAP patients is reported 
to be 10-15% and the cumulative life time risk estimates range between 14-
21% (Gurbuz et al. 1994, Heiskanen et al. 1996, Soravia et al. 2000, Bertario 
et al. 2001, Nieuwenhuis et al. 2008, Campos et al. 2015), whereas among 
the general population frequency is 2-4 per million individuals (Nieuwenhuis 
et al. 2011, Reitamo et al. 1986). Desmoids are predominantly located in the 
abdominal wall or intra-abdominally in FAP patients, whereas sporadic 
desmoid tumours are most commonly found in the extremities. Intra-
abdominal desmoid tumours occur in 10-13% of sporadic desmoids. In 
contrast, 51-72% of desmoids in FAP patients are intra-abdominal (Gurbuz et 
al. 1994, Fallen et al. 2006, Nieuwenhuis et al. 2011). FAP-related desmoids 
appear at younger age than sporadic desmoids (Nieuwenhuis et al. 2011). 
Several risk factors for desmoid tumour formation among FAP patients have 
been reported (Table 6).  
Table 6 Risk factors for desmoid tumours in FAP patients. 
Risk factors for desmoid tumours: 
-APC gene mutation situated beyond codon 1444  
-Positive family history of desmoid 
-Prior abdominal surgery  
(Bertario et al. 2001, Soravia et al. 2001, Nieuwenhuis et al. 2011) 
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Desmoid tumours are classified according to their location: intra-abdominal, 
abdominal wall or extra-abdominal. Intra-abdominal desmoids are the most 
difficult to treat, and these are classified as four stages: stage I for 
asymptomatic, non-growing desmoids; stage II for symptomatic, non-
growing desmoids of 10 cm or less in maximum diameter; stage III for 
symptomatic desmoids of 11 to 20 cm or for asymptomatic slow-growing 
desmoids; and stage IV for desmoids larger than 20 cm, or rapidly growing, 
or with life-threatening complications (Church et al. 2005). 
 
The symptoms of desmoid tumours are related to the site of the tumour. 
Desmoid tumours can obstruct the ureter or bowel when they grow intra-
abdominally. Even though they are histologically benign, they are able to 
invade organs and the abdominal wall and thereby they cause bowel wall 
perforations and fistulas in the gastrointestinal and urinary tracts. The 
natural course of desmoid can vary. (Nieuwenhuis et al. 2011) Spontaneous 
regression has been reported in 10% cases of abdominal/abdominal wall 
desmoids (Burtenshaw et al. 2016). As much as 65% have also reported to 
have stable disease or regression with the ‘wait-and-see’ policy (Fiore et al. 
2009).  
2.7.4 Treatment of desmoid tumours 
Surgery has been the first choice for desmoid treatment, whenever possible 
without major impairment of area in the question. Current desmoid tumour 
treatment has moved towards a more conservative management approach 
(Bonvalot et al. 2012, Briand et al. 2014). It is known that many desmoids 
remain stable or even regress, though desmoid tumour recurrences have 
been reported to occur in more than half of the operated patients (Mullen et 
al. 2012, Stoeckle et al. 2009, Briand et al. 2014). However, extra-abdominal 
desmoids can usually be removed surgically with clear margins and without 
major problems. The more problematic are the desmoid tumours in intra-
abdominal location that they are usually not possible to resect with clear 
margins, curatively. Usually intra-abdominal desmoids are located in the 
mesentery. Thus, complete removal of desmoids would often demand 
substantial resection of the small bowel, which would predispose the patient 
to short bowel syndrome. The surgical treatment of desmoid has also been 
reported to carry a high morbidity and the recurrence rate after surgery is 
considerable. In general, intra-abdominal desmoid removal is not 
recommended, if they are asymptomatic (Kasper et al. 2011).  
 
Desmoid tumours are prone to recur. The resection with the involved 
margins is a risk factor for recurrence (Mullen et al. 2012, Stoeckle et al. 
2009). Some other risk factors such as the patient’s young age, big tumour 
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size and tumour located in the extremities have been suggested for 
independent risk factors (Crago et al. 2013). The overall relapse rate of all 
desmoid tumours is 23-31%, and the 5-year recurrence free survival is 69% 
(Stoeckle et al. 2009, Mullen et al. 2012, Crago et al. 2013, Ihalainen et al. 
2015, He et al. 2015, Burtenshaw et al. 2016). The median time for relapse 
has been reported to be between 14 and 22 months (Stoeckle et al. 2009, 
Mullen et al. 2012, Burtenshaw et al. 2016). The recurrence rate of intra-
abdominal FAP-related desmoids is 22-31%, respectively (Heiskanen et al. 
1996, Nieuwenhuis et al. 2011).  
 
Radiotherapy can be used for extra-abdominal desmoid tumours as an 
adjuvant therapy after surgery with positive margins or as a primary therapy 
when the surgical resection might cause significant impairment. 
Radiotherapy alone or radiotherapy as an adjuvant therapy after surgery has 
resulted in better recurrence free survival than surgery alone (Mullen et al. 
2012, Nuyttens et al. 2000). Radiotherapy has various side-effects (Tsudaka 
et al. 1991). The rate of the side-effects has been estimated in the long follow-
up up to 26% (Guadagnolo et al. 2008). The factors that influence the risk of 
complications have been suspected to be high doses of radiotherapy, the 
patient’s young age and a large area of tumour, which is subsequently treated 
by radiotherapy alone (Guadagnolo et al. 2008).  
 
Some medical agents have been used to restrain the growth of the desmoid 
tumours, such as anti-oestrogens and NSAIDs (Soravia et al. 2000, Janinis et 
al. 2003). These agents have been used mostly for treating recurrent 
desmoids and also those tumours that cannot be resected. The 
recommendation is to start with NSAIDs, such as sulindac and if this fails to 
restrain the tumour growth by an anti-oestrogen, such as tamoxifen, and if 
that approach fails, then cytotoxic chemotherapy such as methotrexate or 
vinblastine can be considered (Janinis et al. 2003). More recently tyrosine 
kinase inhibitors have been introduced for desmoid disease treatment, 
particularly in recurrent diseases (Penel et al. 2011).  
 
The desmoid disease shares the second place in the mortality statistics with 
gastroduodenal cancers in mortality because of the limited treatment options 
for desmoid disease (de Campos et al. 2010). 
2.7.5 Other malign manifestations 
In addition to colonic and upper intestinal manifestations, there are several 
other less frequent manifestations associated with FAP. The risk of 
pancreatic cancer is higher than in the general population. The relative risk 
has been shown to be 4.5 and the absolute lifetime risk 1.7% (Giardiello et al 
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1993). Pancreatic cancer is not easy to detect in its early stages and there is 
no routine surveillance recommended (Groen et al. 2008).  
 
Papillary thyroid cancer is also observed more among FAP patients than 
control populations. The relative risk is around eight and the life time risk is 
2%. Young women are particularly at risk of this condition. At least palpation 
of the thyroid gland is recommended yearly for young women affected, but 
recently ultrasound screening for thyroid cancer has also been recommended 
(Plair et al. 1987, Giardiello et al. 1993, Jarrar et al. 2011).  
 
Hepatoblastoma is an embryonal liver tumour, which occurs predominantly 
among boys from six-months-old to three-years-old. The relative risk of 
hepatoblastoma in FAP families is about 850 and the absolute risk is 1.6% 
(Giardiello et al. 1991, Galiatsos et al. 2006). A family history of 
hepatoblastoma increases a risk for this rare condition. Surveillance is 
organized for these families and it should be started shortly after birth and 
continued until four years old. α-fetoprotein laboratory test and liver 
ultrasound should be organized every three months (Aretz et al. 2006).  
 
Finally the association of brain tumours and FAP has been identified. This 
association of brain tumour and colorectal polyposis was initially called 
Turcot syndrome, as Turcot and colleagues were the first to describe it in 
1959 (Turcot et al. 1959, Hamilton et al. 1995). The relative risk is 7 and 
absolute life time risk is 1-2% (Giardiello et al. 1991, Galiatsatos et al. 2006, 
gene reviews database). The most common type is medulloblastoma. The 
surveillance is not routinely recommended (Galiatsatos et al. 2006, Groen et 
al. 2008). 
2.7.5 Other benign manifestations 
Osteomas are benign osteoblastic growths. They are the most common 
skeletal abnormality associated with FAP. They are usually situated in the 
outer cortex of the skull, paranasal sinuses or the alveolus of the mandible or 
maxilla (Oner et al. 2006). Osteomas have been observed among 46 to 93% 
of FAP patients (Wijn et al. 2007). Usually they are asymptomatic. Large 
osteomas that restrict the movement of the jaw or are cosmetically 
bothersome can be removed surgically. Odontomas (9-83%), benign tumours 
that arise from dental tissue, and supernumerary teeth (11-27%) can be 
detected among FAP patients more frequently than among other population 
(Wijn et al. 2007). An association of osteomas and polyposis in addition to 
skin and soft tissue tumours such as desmoid tumours and thyroid tumours 
has historically been called Gardner’s syndrome (Gardner et al. 1952, 
Järvinen et al. 1982). Of the ski manifestations epidermal cysts are the most 
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common (50-65%) among FAP patients (Bilkay et al. 2004). Other skin 
lesions include the following: lipomas, fibromas, leiomyomas, neurofibromas 
and pigmented skin lesions (Ascari-Raccargi et al. 1999, Bilkay et al. 2004, 
Burger et al. 2011). 
 
Congenital hypertrophy of the retinal pigment epithelium (CHRPE) is a very 
pathognomonic feature of FAP. The condition has been reported with a 
specificity of up to 95% for FAP syndrome (Traboulsi et al. 1987). It is the 
most common extra-colonic manifestation of FAP and an early marker for it. 
The prevalence of CHRPE is 70-75% among FAP patients (Nieuwenhuis et al. 
2007), whereas among the normal population the prevalence is only 1.2% 
(Coleman et al. 2007). It has no effect on the patient’s sight. CHRPE is 
congenital therefore it can be diagnosed at any age. A patient belonging to a 
FAP family can theoretically be screened for CHRPE before polyps arise if the 
mutation of the family has not been detected (Gebert et al. 1999).  
 
FAP patients have an increased risk of adrenal tumours. Most of the tumours 
are incidentalomas and are thus found during otherwise performed 
scanning. The risk of adrenal tumours is reported to be 7-13% (Marchesa et 
al. 1997, Smith et al. 2000). The clinical presentation is same as in sporadic 
patients. The malignant transformation is extremely rare (Barson et al. 
1999). 
2.8 Survival and the causes of death of FAP patients 
2.8.1 Causes of death 
The leading cause of death in FAP patients is still colorectal cancer, mostly 
among the proband population, who usually first appear with the symptoms 
of the colorectal cancer. Colorectal cancer deaths account for 59% to 85% of 
all deaths in FAP patients (Arvanitis et al. 1990, Järvinen 1992, Iwama et al. 
1993, Bertario et al. 1994, de Campos et al. 2010). These high figures also 
include data from the era before systematic surveillance and polyposis 
registries were implemented. With good prophylactic surgery and early 
treatment of colorectal cancer the other extra-colonic manifestations related 
to FAP (ECMs) have become more important causes of death. The most 
relevant of these ECMs are the desmoid tumours and gastroduodenal 
cancers. The incidence of desmoid tumour deaths varies between 0-11% 
(Arvanitis et al. 1990, Iwama et al. 1993, Heiskanen et al. 1996, Bülow et al. 
2003, Campos et al. 2010). The incidence of duodenal cancer deaths is 0-8% 
and gastric cancer 0-5%, respectively (Arvanitis et al. 1990, Iwama et al. 
1993, Bertario et al. 1994, Belchetz et al. 1996, Heiskanen et al. 1996, Bülow 
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et al. 2003, Campos et al. 2010). There are also other less commonly 
occurring tumours related to FAP such as thyroid cancer, hepatoblastoma 
and brain cancer (Iwama et al. 1993, Belchetz et al. 1996). These also cause 
deaths occasionally. Post-operative deaths after prophylactic 
proctocolectomy and pancreaticoduodenectomy can also occur, though less 
than in early days because of better quality of perioperative care and 
standardized operative techniques and centralization of the surgery in high 
volume centers. Surgical mortality was reported in previous series to range 
between 0 to 5.2% (Arvanitis et al. 1990, Bertario et al. 1994, Belchetz et al. 
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2.8.2 Survival and the impact of registries on survival 
The progression of colorectal cancer among FAP patients in earlier times was 
inevitable and this was also the most common cause of death. The first 
polyposis registry was established in St Mark’s hospital in 1924 and since 
that time the survival of polyposis patients has improved. In general, it is 
recommended that all FAP patients are treated and surveyed in the context 
of a FAP registry. National research registry for polyposis patients in Finland 
was established in 1984. After the establishment of registries the incidence of 
CRC diminished (Järvinen 1992).  Colorectal cancer mortality has also been 
significantly reduced (Heiskanen et al. 2000, Barrow et al. 2013). Reductions 
have ranged from a baseline of 44-64% to only 4-6% in colorectal cancer 
incidence among call-ups (Morton et al. 1993, Mallinson et al. 2010). The 
effect of registries and systematic screening and surveillance on overall 
mortality has been controversial, however. There are some studies that 
report significant reductions in mortality after registries, but lately 
controversial results that showed no improvement of overall survival have 
been reported (Heiskanen et al. 2000, Bülow et al. 2003, Gibbons et al. 
2011). It has been suggested that when the colorectal cancer threat has been 
prevented, the incidence of other extra-colonic FAP-related deaths has been 
increased and thus the overall survival has not improved (Gibbons et al. 
2011). 
2.8.3 Life expectancy 
Despite effective screening programmes, life expectancy among FAP patients 
is shortened compared to that of the general population. The life expectancy 
among the screened population has been reported to be 70.4 years, whereas 
among probands it is only 57.8 years (Mallinson et al. 2010). If the groups 
are put together the life expectancy among men is 63.6 and among women 
66.8 years. Furthermore, if the analysis includes data obtained before 1985, 
then the life expectancy was 56.7 years and after 1990 it was 70.6 years. Life 
expectancy of the general population in same region was 78 among men and 
82 among women (Wilding et al. 2012). Life expectancy of FAP patients has 
improved over time and is better among screened, but it is still inferior to 
that of the general population.  
 
 46
3. OBJECTIVES OF THE STUDY 
The objective of this dissertation was to analyse the outcome of different 
operation techniques among FAP patients. The effect of screening on the 
survival was studied in FAP families. The association of the APC gene 
mutation and desmoid disease was studied, as were the differences between 
FAP-related and sporadic desmoid tumours.  
 
The specific study aims were as follows: 
 
1. To compare colectomy and ileorectal anastomosis (IRA) and 
proctocolectomy and ileal pouch-anal anastomosis (IPAA) as a 
treatment in FAP patients (I). 
 
2. To determine the risk of secondary proctectomy and the risk of rectal 
cancer in patients, who have undergone colectomy and IRA (II). 
 
3. To study the impact of screening on survival (III). 
 
4. To detect the APC gene mutations among desmoid tumour patients 
(IV). 
 
5. To compare the characteristics and the treatment of sporadic and 




4. MATERIALS AND METHODS 
4.1 Patients  
4.1.1 A nationwide study that compared IRA and IPAA, and reports 
the risk of secondary proctectomy and cancer after IRA (I, II) 
The prophylactic operative treatment of FAP patients by colectomies and IRA 
was started in Finland in 1963. The first proctocolectomy and IPAA for FAP 
patient was performed in 1992. Before then the options were IRA or 
proctocolectomy and Brooke’s ileostomy. From the beginning of 1992 
onwards all the Finnish FAP patients operated by IRA or IPAA were included 
in the Finnish polyposis registry. All the data of these patients were 
retrospectively collected from the polyposis registry files in addition to data 
of the clinical patient files. The survival information was collected from the 
Finnish Cancer Registry and Finnish Population Register Center. The genetic 
testing for FAP patients became available in Finland in the year 1996. The 
genetic information has since influenced the choice of the operation.  Prior to 
the establishment of IPAA, IRA was the operation of choice for all patients 
who had mild or moderate polyposis with limited count of rectal polyps that 
could be endoscopicly removed (Table 8). After the introduction of IPAA for 
FAP patients, patients with moderate or severe polyposis were generally 
operated on with IPAA. After IRA the remaining rectum was followed-up by 
endoscope every year. The endpoint for survival was the date of death or the 
last day of the study period (30th September 2012). At the time of the last day 
of the study period 30th September 2012, there were a total of 228 operated 
patients. More than one-third 88 (39%) patients had undergone IPAA 
compared with 140 (61%) patients who had undergone IRA. Furthermore, 
these 140 IRA patients were included for further study about secondary 
proctectomy. 
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Table 8 Indications for IRA and IPAA operations 
 
1) Church et al. 2001, 2) Wu et al. 1998, 3) Vasen et al. 2008, 4) Campos et al. 2009 
4.1.2 Study of the effect of screening (III) 
The nationwide study of 154 families with at least one FAP patient comprised 
a total of 421 patients. Two of these 421 patients were excluded: one because 
the diagnosis of FAP was confirmed after death and another because of 
missing follow-up information. The data from the year 1963 until end of the 
study period on April 30th 2015, were collected. Patients were divided 
between probands and call-ups. Probands were found because they 
manifested symptoms and the call-ups were their relatives, whom had been 
invited for a screening during which FAP was found.  
4.1.3 Association of desmoid tumours and an APC gene mutation and 
comparison of sporadic and FAP-related desmoids (IV, V) 
The data of the desmoid tumour patients from the year 1980 to the 30th April 
2015 were collected from the database of the Department of Pathology, 
Helsinki University Hospital. A total of 221 patients were identified as having 
desmoid tumour in any part of the body. Patients between the years 2000 to 
2012 were included in the prospective part of the study, which was carried in 
2013. The data were collected from the patient files. The prospective phase of 
the study included 106 patients. Twenty-one of these patients had already 
undergone endoscopic FAP screening. The remaining 85 were invited to a 
screening. In the end total of 52 (61% of all invited patients) patients 
participated in the FAP screening. Of these 52 patients five had recently 
undergone endoscopy and they did not participate in the endoscopy part of 
 Pre IPAA and pre gene testing era IPAA era 
 C+IRA PC+Ileostomy C+IRA PC+IPAA 
Rectal polyp count Low High <5 polyps >20 polyps 1) 
Rectal cancer No Yes No Yes 














To avoid annual 
rectoscopies, one 
step operation 
Desmoid tumour   
May prevent future 
IPAA Preferable 3) 
Comorbidity Safe Safe Safe 
More 
complications 4) 
AFAP Preferable  Preferable 3)  
Mutation  - - Low risk site High risk site 2) 
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the screening. All patients met a colorectal surgeon with experience of 
hereditary colorectal cancer who gave each an information about the gene 
test, performed a sigmoidoscopy and asked each patient for a written consent 
for genetic testing. APC germline mutation testing was conducted first by 
standard exon-specific sequencing for point mutations. If a negative result of 
the test was received the MLPA test was conducted with the intention of 
finding large rearrangements. MLPA testing was carried out in the 
Department of Medical Genetics of Helsinki University. 
 
Further retrospective analyses comprised all 221 desmoid tumour patients. 
Patient and tumour characteristics were analyzed and these were: tumour 
size and location, treatment, the margin status of the spesimens, recurrences, 
median follow-up time, age at diagnosis and the recurrence free survival. 
APC gene mutations among the FAP patients were recorded if known. Only 
those patients with primarily R0 or R1 resection were included in the dataset 
for the recurrence free survival analysis. 
4.1.4 Ethical aspects 
The operative ethics committee of Helsinki University Hospital approved all 
the parts (I-V) of this study. For the prospective part of the study (study IV) a 
written informed consent was obtained from every patient before taking a 
blood draw for genetic testing or endoscopy. The FAP research registry has 
obtained a research permit from the Ministry of Social Affairs and Health 
(No 1922/69/86) and the permit has recently been renewed in National 
Institute for Health and Welfare (Dno THL/1068/5.05.00/2015). All FAP 
patients have given written informed consent for mutation testing at the time 
of mutation testing, also outside of this study. Relatives have not been 
contacted without the permission of the proband. All families with a 
suspected hereditary disposition have been offered information about the 
gene test and the possibility for further diagnostics and treatment. 
4.2 Scoring systems 
A Clavien-Dindo classification was used for grading the complications. This 
classification categorizes the surgical complications from grades 1 to 5 
according to invasiveness of the action required to treat the complication 
(Table 9). 
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Table 9 Clavien-Dindo classification 
Grade Definition 
0 No complication 
1 Any deviation from the normal postoperative course without the need for 
pharmacological treatment or surgical, endoscopic or radiological interventions. 
2 The complication requiring pharmacological treatment. 
3a Surgical, endoscopic, or radiological intervention required that is not done under 
general anaesthesia. 
3b Surgical, endoscopic, radiological intervention done under general anaesthesia 
4 Life threatening complication requiring intensive care unit management, multi-
organ dysfunction 
5 Death 
(Dindo et al. 2004) 
 
The classification of American Society of Anaesthesiologists (ASA) was used 
for assessing the patients’ clinical condition and comorbidies, and the patient 
related risks of the surgery. Patients were classified into three categories ASA 
1, ASA 2 or ASA 3 and above. ASA 1 refers to a normal healthy patient, ASA 2 
to patient with mild systemic disease, and ASA 3 patient with severe systemic 
disease.  
 
The extent of desmoid tumour resection was defined thus, the margin status 
was classified as no residual tumour (R0), microscopic residual tumour (R1) 
or macroscopic residual tumour (R2) according to the American Joint 
Committee on Cancer (AJCC) criteria, 7th edition (Edge et al. 2010).  
4.3 Statistical analyses  
4.3.1 I-II and IV-V 
We used Kaplan-Meier survivorship curve analysis to evaluate the 
cumulative overall survival (I, II, V). The differences in survival curves were 
assessed by a log rank test. Proportions of events were compared by Pearson 
exact chi square, Fisher’s exact tests and 2-tailed tests were used. The p-
values below 0.05 were considered statistically significant. The independent 
samples t-test was used for comparing the differences between two groups 
that were continuous and normally distributed. The Mann-Whitney U test 
was used to compare the distributions between two groups as ordinal 
variables. When we studied the factors possibly affecting the survival 
multivariate Cox regression analysis was used (I). The factors studied were 
ASA classification, mutation type, histology, and rectal cancer. Factors with 
p<0.1 in the Kaplan Meier analyses were included in the Cox analysis; all 
parameters except the mutation type fulfilled this criterion. Cox analysis was 
adjusted for age, sex, and hospital type. No significant interactions were 
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found when the interaction terms were tested. Time dependent covariate was 
included separately for each testable variable for testing the Cox model 
assumption of constant hazard rations over time. All included variables 
fulfilled the Cox model assumption. Statistical analyses were performed 
using SPSS software (IBM Corp., New York, NY). 
4.3.2 III 
We compared survival and mortality between probands and call-ups. The 
follow-up started from the day of the diagnosis of the probands and for the 
called-up patients from the day they attended the first screening. The end of 
the study period was either death or the last day of the study period, April 
30th 2015. The crude mortality rate and the number of deaths in a patient 
population within a year per 1000 of population counted at midyear were 
reported. The mortality ratio between two groups was calculated and 
recorded. Mortality rates were compared to the general Finnish population at 
the same age, standardized mortality ratio (SMR). SMR was counted 
separately for probands and call-ups. Rates and rate ratios were calculated 
using standard Poisson regression with log-link. Relative survival was 
estimated using the method introduced by Ederer (Ederer II). The relative 
survival is the ratio of the observed survival of a FAP patients compared to 
the expected survival of a comparable cohort of FAP free individuals or in 
this study the general population at the same age and of the same sex (Ederer 




5.1 Comparison of IRA and IPAA (I, II) 
5.1.1 Surgical Outcomes  
A total of 228 FAP patients underwent IRA or IPAA operation. Of the 140 
IRA patients, 49 were performed after the IPAA procedure had become an 
available option for FAP patients, thus 91 IRAs were performed before 1992. 
Furthermore 39 of the IRA operated patients underwent a secondary 
proctectomy. The patient characteristics are presented in Table 10.  
Table 10 Characteristics of patients who had undergone an operation 
  
 
The diagnosis of FAP was made by endoscopy for 204 (89%) of patients, 
most of which were done before the genetic testing had become available. 
There were six patients in the IRA group whom had a mutation in a high risk 
site (codon 1250-1464) and whom were operated before the genetic testing or 
IPAA procedure were available. After IPAA was introduced among FAP 
patients in Finland all eight high risk mutation patients were operated on by 
IPAA.  The ASA classes of the patients at the time of IRA and IPAA are 
presented in Table 11. 
  
Variable IRA IPAA Secondary 
proctectomy 
N 140 88 39 
Gender, F:M 81:59 39:49 24:15 
Age at operation 
Mean (SD)  
36 (14)  30 (12) 45 (11) 
Follow-up time after operation  
Median years (IQR) 
20.7 (7.7-27.4) 9.7 (4.6-15.6) 10.3 (2.2-
14.7) 
Proband:call-up 58:82 28:60 16:23 
Expression type 
FAP:AFAP 
123:17 85:3 37:2 
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Table 11 ASA classes of the IRA and IPAA operated patients 
Mann-Whitney U p=NS 
 
The median hospitalization time was nine days for the entire IRA group and 
from the year 1992 on it was eight days. Hospitalization time for the IPAA 
group was also nine days. Complications were detected in 28 (21%) of 135 
patients in the IRA group (data was missing in five cases), whereas 26 (30%) 
of 87 patients in IPAA group had complications (data missing in one case) 
(Table 12).  
Table 12 The severity of complications and specific complications after IRA and IPAA 
operations  
Mann-Whitney U of Clavien-Dindo class p=NS 
 
There were no differences in the overall complication rates between the 
groups (p=NS). There were tendency toward more severe complications 
Variable IRA IPAA 
ASA class:   
ASA1 87 (62%) 54 (61%) 
ASA2 30 (21%) 26 (30%) 
ASA3 or more 10 (7%) 2 (2%) 
No data 13 (9%) 6 (7%) 




Clavien-Dindo class:    
1 11 (8%) 5 (10%) 8 (9%) 
2 1 (1%) 0 10 (11%) 
3a 1 (1%) 1 (2%) 3 (3%) 
3b 13 (10%) 4 (8%) 5 (6%) 
4 1 (1%) 1 (2%) 0 
5 1 (1%) 0 0 
Specific complications:    
Wound infection 1 (1%) 1 (2%) 2 (2%) 
Abscess 4 (3%) 0 3 (3%) 
Leakage 9 (6%) 4 (8%) 2 (2%) 
Haemorrhage 1 (1%) 0 5 (6%) 
Ileus 3 (2%) 1 (2%) 2 (2%) 
Other postoperative 9 (6%) 5 (10%) 12 (14%) 
Post operative death (within 30 days) 1 (1%) 0 0  
Total 28 (21%) 11 (22%) 26 (30%) 
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(Clavien-Dindo ≥3b) in the IRA group compared to the IPAA group; 15 (11%) 
vs. 5 (6%). This same tendency in complications was seen when IRA 
operations were performed in the IPAA era, five (10%) in IRA group. 
Complications were associated with a higher ASA classes (ASA class 1, 19%: 
ASA class 2, 36%: ASA class 3–4, 33% p = 0.04). Re-operations due to 
complications within 30 days were performed for 13 (9.6%) patients of the 
IRA group, for four (8.2%) patients operated by IRA from the year 1992 
onwards and for six (6.9%) of 87 patients of the IPAA group. There were 23 
(16%) cancers detected in IRA specimens and severe dysplasia was found in 
13 (9%) specimens. Among IPAA operation there were 11 (13%) cancers and 
19 (22%) severe dysplasias. In rest of the specimens, there were mild 
dysplasia or no dysplasia.  
 
Altogether 39 (28%) of patients in the IRA group underwent secondary 
proctectomy a median of 14 years after the primary operation. The 
cumulative risk for secondary proctectomy was 5% at five years, 30% at 20 
years and 53% at 30 years after the primary operation (Figure 8).  
 
 
Figure 8 Cumulative risk of secondary proctectomy after IRA. 
There were 24 (62%) secondary proctectomies done initially with IPAA, but 
five (21%) of these 24 pouches were finally converted to permanent 
ileostomies. Two of these were performed because of postoperative 
haemorrhage and leakage and three because of chronic anal incontinence. A 
total of 21 (15%) of patients with IRA finally ended up with permanent 
ileostomy. The median time for ileostomy after IRA was 16 years. The ileal 
pouch was removed and converted to ileostomy in three (3.4%) patients. The 
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median time for ileostomy after the IPAA procedure was 2.4 years. Two 
AFAP patients underwent secondary proctectomy, and both of these were 
because of profuse polyposis. The reasons for secondary proctectomies and 
permanent ileostomies performed in connection with secondary 
proctectomies are presented in Table 13. 
Table 13 Indications for secondary proctectomies and permanent ileostomies in 
secondary proctectomy operation. 
 
A total of 48 proctocolectomies with ileostomy were initially performed 
without an attempt to save the anus. Sixteen of these were carried out after 
the introduction of the IPAA technique. The indication for proctocolectomy 
with permanent ileostomy before the year 1992 was rectal cancer in 18 
patients and severe polyposis in 14 patients. After 1992, low rectal cancer was 
the indication for permanent ileostomy in 11 patients and severe polyposis in 
5 patients. 
5.1.2 Rectal cancer rate and survival after the primary operation 
The median follow-up time after IRA was significantly longer than after IPAA 
(20.7 vs. 9.7 years, p<0.001). There were 18 (13%) patients diagnosed with 
postoperative rectal cancer. All of these cancers were in the IRA group. The 
mean time for rectal cancer occurrence after IRA was 16 years. There were 
six proctectomies with IPAA and six proctectomies with ileostomy performed 
because of rectal cancer. No rectal cancers were detected among the AFAP 
patients. There were no cases of rectal or ileal pouch cancer in the primary 
IPAA group. The cumulative risk of rectal cancer was 3% at 5 years and 5% at 
15 years (Figure 9), but from the year 1992 onwards the cumulative risk for 
operated patients was 0 until 15 years. 








Cancer or suspicion of cancer 17 (44%) Before the IPAA era 7 (33%) 
Profuse polyposis 17(44%) Distal rectal cancer 4 (19%) 
Anal incontinence 2 (5%) Mesenteric desmoid 2 (10%) 
Patients wish 3 (8%) Patients wish 3 (14%) 
  Failed IPAA 5 (24%) 




Figure 9 Cumulative risk of rectal cancer after IRA operation. 
Rectal cancer deaths were detected in 10 patients, which equates to a rectal 
cancer mortality of 7%. There was no rectal cancer related deaths after IPAA 
era operated IRAs. The five years survival rate after rectal cancer diagnosis 
was 55%. Cumulative risk of death of rectal cancer after IRA was 2% at 5 
years and 3% at 15 years (Figure 10).  
 
Figure 10 Cumulative risk of rectal cancer death after IRA operation. 
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The overall survival was lower after IRA than after IPAA (p=0.03): 88% vs. 
96% at 10 years, and 84% vs. 96% at 15 years (Figure 11).  There was no 
significant difference in overall survival (p=0.06) between IRA and IPAA 
groups after IPAA technique was adopted though there is a tendency toward 
better survival in the IPAA group (Figure 12). The age-specific survival was 
also lower after IRA than after IPAA (p=0.003): 98% vs. 98% at 30 years, 
93% vs. 98% at 40 years, 86% vs. 98% at 50 years, and 73% vs. 89% years at 
60 years of age. 
  
Figure 11 Cumulative survival after IRA and IPAA operations. 
 




Cox regression analysis revealed that patients with higher ASA classifications 
had a worse survival (ASA 3: HR 5.3, 95%CI: 1.3-22, p=0.02). Postoperative 
rectal cancer reached significance as an independent risk factor as well (HR 
2.4, 95%CI: 1.0-5.6, p=0.046). The histology of specimen (benign, high grade 
dysplasia or cancer) did not reach statistical significance as an independent 
risk factor. 
 
Causes of death among IRA and IPAA operated patients are presented in 
Table 14. All the rectal cancer deaths were among IRA patients operated 
before the IPAA era. In attenuated FAP patients (17 with IRA and 3 with 
IPAA) there were no cancer-related deaths. From the 1992 onwards operated 
IRA patients there were three deaths: one gastric cancer related death, one 
desmoid tumour related death and one non-FAP related cancer death. 
Table 14 Causes of deaths after the operation 
Cause IRA IPAA p-value 
Rectal cancer 10 (7%) 0 0.02 
Colon cancer 2 (1%) 0 NS 
Duodenal or pancreatic cancer 4 (3%) 0 NS 
Gastric cancer 2 (1%) 1 (1%) NS 
Desmoid tumor 3 (2%) 1 (1%) NS 
Postoperative death 1 (1%) 0 NS 
Other cancer 3 (2%) 1 (%) NS 
Other 14 (10%) 0 0.003 
Total 39 (33%) 3 (3%) <0.001 
 
5.2 Survival differences between call-ups and probands 
(III) 
A total of 194 probands were found. Among the call-ups, initially 83 patients 
were diagnosed by a gene mutation test, and 142 patients were diagnosed by 
endoscopy. All had undergone endoscopy afterwards. Among the currently 
alive Finnish FAP patients 274 (92%) of 297 belong to families with a known 






Table 15 Characteristics of all FAP patients. 
  Probands Call-ups Total 
Patients (No) 194 225 419 
Gender F:M 116:78 106:119 222:197 
Age at diagnosis (Mean, SD) 39 (14)  27 (15) 33 (16) 
Follow-up time years (Median, IQR) 9 (3-24) 14 (7-24) 12 (4-24) 
 
Mortality rates are reported in Table 16 with their 95% confidence intervals 
(CIs). There was a difference in mortality rates between probands and call-
ups. There was also a difference in total SMR. The SMR in the proband group 
was elevated at the beginning of the follow-up and then after 10 years it 
decreased slowly. The SMR remained at about 2 for the call-ups until 20 
years after diagnosis.  
Table 16 Crude mortality and standard mortality ratios according to group at 95% 
confidence intervals. 
SMR=standardized mortality ratio, #Testing SMR (Proband) vs. SMR(Call-up) p=0.014 
 
The relative survival for probands was lower than for the call-ups (p<0.001). 
Relative survival for call-ups remained at the approximate level to that of the 
general population up to 20 years after the initial diagnosis. The relative 










Patients 194 225 
Deaths 92 30 
Crude mortality rate 34.9 (28.4-42.8) 8.3  (5.8-11.8) 
Risk ratio (95%CI) 1.0 0.24 (0.16-0.36) 
SMR 0 years (95%CI) 16.4 (12.3-21.3) 1.65 (0.51-3.82) 
SMR 5 years (95%CI) 5.00 (2.75-8.24) 2.07 (0.64-4.82) 
SMR 10 years (95%CI) 1.44 (0.45-3.35) 2.16 (0.67-5.03) 
SMR 20 years (95%CI) 1.79 (0.64-3.85) 4.35 (1.87-8.41) 
SMR 30 years (95%CI) 2.18 (1.13-3.74) 0.68 (0.04-2.98) 





Figure 13  Relative survival compared to comparable population 
Causes of deaths and median ages at death for both probands and call-ups 
groups are listed in Table 17. There were a total of 122 deaths during the 
follow-up time. The FAP-related causes were the predominant reason for the 
deaths. As much as, 52% (64 of 122) of FAP patients died of colorectal 
cancer, 11% died of other FAP-related cancers, 3.3% from desmoid related 
deaths and 2.5% died of post-operative complications. The proband groups 
had significantly (p<0.001) more deaths due to colorectal cancer than their 
call-up counterparts. There were no differences between the groups for extra-
colonic FAP-related deaths (p=NS).  
  
Years  5 10 15 20 25 30 
Relative 
survival  
Proband 74% 67% 67% 66% 64% 64% 
Call-up 99% 98% 96% 94% 87% 79% 
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Table 17 Death causes of all FAP patients. 
Death cause Median age Number of 
deaths (%) 
Median age Number of 
deaths (%) 
 Probands n=194 Call-ups n=225 
Colorectal cancer 47.4 56 (61) 58.9 8 (27) 
Pancreatic/duodenal cancer 60.3 5 (5) 51.9 4 (13) 
Gastric cancer 54.5 3 (3) 29.2 1 (3) 
Post-operative complication 53.7 3 (3)  0 (0) 
Desmoid tumour 26.1 1 (1) 37.2 3 (10) 
Medulloblastoma  0 (0) 22.4 1 (3) 
Other cancer 55.6 6 (7) 57.7 3 (10) 
Other or unknown 68.9 18 (20)  58.2 10  (33) 
Total 53.7 92 (100) 56.2 30 (100) 
 
5.3 APC gene mutation in desmoid tumour patients (IV) 
There were 13 (12%) FAP patients among 106 patients with desmoid 
tumours.  Ten of these desmoid patients had FAP diagnosis before the 
desmoid disease manifested, but the remaining three had a desmoid 
diagnosis first and the FAP screening was carried out because of this 
diagnosis. All three of these FAP patients had endoscopy first, then the APC 
gene mutation was subsequently found. The mutations were found in exon 8 
codon 283, exon 15 codon 1547 and exon 15 codon 2004 of the gene. During 
prospective study 52 patients underwent APC gene mutation testing and 45 
of them also had sigmoidoscopy. There were no new FAP cases found upon 
the endoscopy or in the gene mutation testing in addition to the three cases 
that already had identified mutations. Thus the overall APC mutation rate for 
initially sporadic desmoid patients was 4.8% (3/63). Two variants of 
unknown significance in the APC gene were found among the tested patients. 





Figure 14 Flowchart about prospective study protocol and results. 
5.4 Comparison of sporadic and FAP-related desmoid 
tumours (IV, V) 
At the time of their diagnosis the FAP patients were predominantly younger 
than those patients with the sporadic disease, and the gender distribution 
was equal among them. All the desmoids among the 22 FAP-related desmoid 
tumour patients were located intra-abdominally or in the abdominal wall. 
Among sporadic counterparts the location of the desmoids was mostly 
elsewhere (other truncal or extremities). There were 16 patients who had 
multiple desmoids, 12 of which were in the FAP desmoid group. The patients 
in the sporadic desmoid group were predominantly females who were about 
10 years older than those of the FAP group. The desmoids of the sporadic 





Table 18 Comparison of sporadic and FAP-related desmoids. 
 
5.5 Treatment of sporadic and FAP-related desmoid 
tumours (V) 
Previous pregnancy, surgery or other trauma preceded the 39% of sporadic 
desmoids and 64% in FAP desmoids. A total of 198 (90%) patients were 
given surgical treatment (Table 19). There were no data available on the 
treatment of one of the 221 desmoid tumour patients. Noninvolved margins 
were more common in the sporadic group, whereas half of the operations in 
FAP-related desmoid group were intralesional. Half of the 18 intralesional 
operations did not require any further treatment during the follow-up time. 
Six patients received adjuvant medical therapy and 17 patients received 
adjuvant radiotherapy. All the patients with adjuvant medical therapy had 
FAP. Radiotherapy was given as the first treatment to nine (4.6%) of all 
patients. Two of these nine patients also had medical therapy. Regression or 
stable diseases was noted in six patients of the sporadic desmoid group after 
receiving irradiation treatment. There was a wide variation in medical agents 
used: thyrosine kinase inhibitors, immunosuppressants, anti-oestrogens and 
cytostatic agents. Fourteen patients were initially treated according to the 










Female / male 145 / 54 10 / 12 0.008 
Age at diagnosis (years), mean 
(SD) 
42.4 (16.4) 30.5 (9.9) 0.001 





























Multiple desmoids 4 12 <0.001 





























Recurrence after operation 42 4 NS 
Mean time in years 2.42 (SD 3.69) 2.18 (SD 0.99) NS 
Recurrences after primary 
















Recurrences were detected in 42 (25%) of sporadic desmoid patients and in 
four (44%) of FAP patients who initially had their tumours completely 
removed. R0 resected tumours recurred in 15 (14%) cases and R1 in 29 (41%) 
cases. The mean time for recurrences to occur was two years. Of the 46 
recurrences, 31 (67%) were treated surgically, 9 (20%) by radiotherapy and 4 
(9%) were only followed-up (there are no data available on the treatment of 2 
(4%) recurrences).  
 
FAP-related desmoids caused death in three cases. There were no deaths 
related to sporadic desmoids. Sixteen patients of the FAP-related desmoids 
had a known point mutation in the APC gene. Half of these mutations were 




6.1 IRA and IPAA (I, II) 
The overall survival of operated FAP patients was better for the 
proctocolectomy and IPAA groups than for the colectomy and IRA groups. 
The overall survival of IRA operated patients was diminished mainly because 
of deaths related to rectal cancer. There were no rectal cancer deaths 
detected for the IRA patients, who had been operated after the IPAA era 
commenced in 1992. Among AFAP patients there were no rectal cancers 
detected after IRA operation. 
 
Postoperative morbidity rates were 21% for the IRA group and 30% for the 
IPAA group. Re-operations were done for 9.6% after IRA and for 6.9% of 
patients after IPAA. These differences in morbidity or reoperation rates were 
not significant, however. Previous studies that compared IRA and IPAA 
complication rates have hitherto been very inconsistent. IRA related 
complications have been reported to range from 0% to 28% of operations 
whereas those of IPAA related complications from 10% to as high as 60% of 
the operations (Madden et al. 1991, Ambroze et al. 1992, Tonelli et al. 1997, 
Soravia et al. 1999, Björk et al. 2001, Günther et al. 2003, Campos et al. 
2009). Generally these studies reported more complications and 
reoperations after IPAA. The overall complication rates reported in a meta-
analysis that compared IRA and IPAA operations did not reach statistical 
significance, but the reoperation rates were significantly different 23% for 
IPAA vs. 12% for IRA (Aziz et al. 2006). Our morbidity rates are close to the 
median of these previously reported figures even if our complication rate and 
reoperation rate was not bigger after IPAA. The reoperation rate in our 
cohort was clearly less than found in the meta-analysis. There was a tendency 
in our study towards more severe complications in the IRA group (Clavien-
Dindo >3b). This same difference remained when taking into account 
operated IRA patients prior to 1992. This is somewhat surprising, because 
IRA has been regarded as an easier procedure in general. In IRA group there 
were more leakages, which is an unexpected outcome, too. The higher 
incidence of these severe complications in our IRA group might be explained 
by the fact that the patients in the IRA group were older than those of the 
IPAA. Although all of the patients were young compared to general age of 
colorectal patients. In IRA group there were 7% of patients with ASA class 3 
or more, where as in IPAA group only 2%, though this difference wasn’t 
significant. In addition, some of the IRA operations were performed in the 
days of less developed perioperative patient care. Among IPAA patients there 
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were more postoperative haemorrhages and other non-surgical postoperative 
complications. This may be related to IPAA being generally more challenging 
procedure than IRA.  
 
The risk of rectal cancer and rectal cancer death is the major concern after 
having IRA. It is the main determining factor on a patient’s prognosis and on 
the need for a secondary proctectomy. Furthermore, when the secondary 
proctectomy is necessary, anus preservation is matter of great importance. 
The rectal cancer rate in our study was 13%, and the corresponding rectal 
cancer death rate was 7%. This is the same level as that of previously 
published results and when taken into account our long study period median 
of 21 years, it is even quite a good result. A previous meta-analysis calculated 
the risk of rectal cancer to be 5.5%. The median follow-up time in that study 
was eight years (Aziz et al. 2006). More recently, the risk of rectal cancer was 
found to be 11% over a median of 15 years follow-up time (Sinha et al. 2010). 
The cumulative rectal cancer risk has been estimated to be 17% after five 
years, 24% after 10 years, and 43% over 15 years (Campos et al. 2009). Those 
figures are far higher than the 3% at 5 years, 4% at 10 years and 5% at 15 
years figures we obtained in the present study. The cumulative risk of rectal 
cancer death stayed relatively low within 30 years after IRA, but even if IRA 
had been done in patients’ thirties, there was a substantial 9% risk of death 
due to rectal cancer at about their 60s. Our low risk of rectal cancer after IRA 
may indicate the successful patient selection, based on patients’ phenotype, 
genotype, preferences and family history, and meticulous yearly follow-up. In 
addition majority of the patients were operated and followed-up by one 
experienced center and furthermore a few experienced surgeons. The rate of 
rectal cancer death in our study compared to rectal cancer rate indicates that 
the rectal cancer prognosis is no better among IRA patients compared to 
overall sporadic rectal cancer prognosis. This is somewhat surprising 
considering yearly organised endoscopic follow-up visits. In part, this may be 
due to the fact that before the IPAA era patients with quite profuse polyposis 
could also undergo IRA in order not to end up with permanent stoma. Yearly 
organized endoscopic visits have reported to diminish colorectal cancer 
mortality among call-up population (Mallinson et al. 2010).  
 
The rectal cancer and polyposis that was uncontrollable by endoscopy were 
the indications for secondary proctectomy in the majority (95%) of cases in 
our study. A total of 28% of the IRA patients eventually had secondary 
proctectomy. Our follow-up time after IRA was long and indeed the risk of 
secondary proctectomy began to increase more than 15 years after the first 
surgery. The cumulative risk rate of 53% by 30 years indicates that over the 
half of the patients will need proctectomy during their lifetime. Another 
study by Sinha and colleagues reported a 29% rectal failure rate, and that by 
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the age of 60 years half of the patients had retained their rectum (Sinha et al. 
2010). Those authors’ results are in line with our results. The secondary 
IPAA was performed for 62%, but 5 (21%) of these patients eventually had 
ileostomy. Thus the anus preservation rate after IRA was finally 49% in our 
study. Our 21% pouch failure rate was far more than 5% pouch failure rate 
reported earlier when IPAA as a primary operation for ulcerative colitis and 
FAP (Lepistö et al. 2002, Fazio et al. 2013). This might reflect that the 
secondary proctectomy would be technically more demanding. Previous 
studies, which compared primary and secondary IPAA, reported higher 
frequency of intra-operative difficulties in secondary proctectomy (Penna et 
al. 1993, Bülow et al. 2013). In one study there were more postoperative 
complications after secondary proctectomy (Björk et al. 2001), whereas 
others have not been found differences in postoperative complications 
among primary and secondary proctectomy (von Roon et al. 2008, Bülow et 
al. 2013). However, there have not been reported differences between the 
cumulative five-year failure rates for primary and secondary proctectomy, 
9% and 8% (von Roon et al. 2008). The most common reason for pouch 
failure was anal incontinence in our cohort. This same reason for pouch 
failure has been noted earlier in other studies (Hahnloser et al. 2007).  
 
There were more deaths in the IRA group, and these also included not FAP-
related causes. This higher death rate may reflect that the follow-up time for 
the IRA group was twice as long as for the IPAA group. The survival benefit 
of IPAA patients after 1992 was not statistically significant. This is in line 
with Yamaguchi and colleagues who reported no difference in survival 
between IRA and IPAA groups (Yamaguchi et al. 1996). This may be a result 
of the hopefully better patient selection after the IPAA technique was 
adopted. On the other hand, the median follow-up time for IRA after the 
IPAA era had ensued is shorter and thus there may still emerge new rectal 
cancers in IRA patients in the future. Some studies attempted to demonstrate 
the better survival in the IRA group after IPAA came available. An 
international study reported a rectal cancer rate of 10% in the pre IPAA era 
compared with only 2% in the IPAA era. However, this study did not detect a 
significant difference in the cumulative survival of these groups and part of 
the survival benefit in the IPAA era operated patients is likely to be explained 
by the shorter follow-up (Bülow et al. 2008), which might be the reason for 
better survival also in our study. Another study reported rectal cancer rates 
of 13% and 0% before and after the adoption of IPAA, respectively (Church et 
al. 2003). Nevertheless, they had the same problem as we have with shorter 
follow-up time for the IPAA era operated patients (Church et al. 2003). After 
having both operations, IRA and IPAA, patients still carry a risk of FAP-
related cancer death. It will not be until we obtain data obtained over a very 
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long follow-up time after the adoption of IPAA, that we can draw definite 
conclusions about the preferable operation type for the FAP patients with 
mild rectal polyposis. 
 
When choosing the operation type for an individual patient, the mutation 
status must also be kept in mind. Our data are partly historical from the time 
before the genetic testing. After IPAA and genetic testing became available in 
1996, all the patients who had a high risk mutation site (codons 1250-1464) 
were operated on with primary IPAA. There were only two (10%) secondary 
proctectomies performed on patients who had AFAP and IRA operation 
performed earlier. Other studies have also emphasized the low risk of 
secondary proctectomy in the AFAP group, and a high risk with the severe 
genotype (Nieuwenhuis et al. 2009).  
6.2 Success of screening (III) 
We found in our nationwide population-based study that screening of FAP 
patients reduces overall mortality and improves relative survival when 
compared to the general Finnish population.  The benefit in diminished 
mortality comes from the significant reduction of deaths due to colorectal 
cancer for the screening population who have an opportunity to undergo 
surgery at right time. There was no difference among call-ups and probands 
for other FAP related deaths (part of which are not screenable). The 
conclusions in earlier studies about the survival benefit of screened 
population have been controversial. Some studies have observed a significant 
difference in survival (Bülow et al. 1995, Heiskanen et al. 2000, Mallinson et 
al. 2010). However, one other study found there was no benefit gain in terms 
of overall survival when starting follow-up from birth (Gibbons et al. 2011). 
    
We preferred to use the relative survival estimation for both groups 
separately to diminish the biases related to the entry of different ages to 
study. This method compares the survival of populations with same age and 
gender. Estimating the survival is prone to biases. The achievement and 
interpretation of survival studies can fail when the concept of the impacts of 
biases is not understood. The fundamental question is: What is the starting 
date of the follow-up when survival is estimated? Lead-time bias suggests 
that the natural history of the disease is not truly affected by screening. The 
advantage in time gained by call-ups in diagnosing the disease earlier is lost 
when starting follow-up at the same age. If follow-up among FAP patients is 
started from the first visit to the clinic, then the follow-up group without any 
symptoms will have a lead-time in comparison to proband group that 
presents with symptoms about 15-20 years later (lead time bias). Immortal 
time on the other hand refers to time during which the death of patient 
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cannot occur. If follow-up is started from the day of birth especially for a 
member of the proband group, then that individual will gain immortal time, 
which will be equal to the interval of time from the birth to the first day of the 
disease (immortal time bias).   
 
We also estimated the relative survival starting from the birth to study 
possible biases. The survival benefit for call-ups diminished but was not 
entirely lost, and here immortal time bias exists for both groups when the 
survival before the age of 3o seems to be over 100%. Finally, we 
demonstrated the survival by starting the follow-up for every family from the 
day of the proband’s entry into the clinic. This diminished the lead-time bias. 
With this method the survival benefit of call-ups also stayed (Figure 15).  
 
 




There were no differences between the causes of death regarding extra-
colonic FAP-related deaths between these two groups. Previously, a 
difference in extra colonic causes in favour of probands had been reported 
(Gibbons et al. 2011). In total, 21 extracolonic FAP-related deaths occurred in 
our series, which is 17% of all deaths. Previously, reported death rates due to 
FAP-related extracolonic reasons have varied been 6% and 27% (Arvanitis et 
al. 1990, Vasen et al. 1990, Iwama et al. 1993, Bertario et al. 1994, Belchetz et 
al. 1996, Heiskanen et al. 2000, Bülow et al. 2003, Campos et al. 2010). 
Colorectal cancer was still the leading cause of death among FAP patients in 
earlier studies, just as it was for 52% of all patients in our cohort. Other 
groups have reported higher figures 59-85% for death from colorectal cancer, 
which perhaps reflects the higher proportion of probands in those studies 
(Arvanitis et al. 1990, Vasen et al. 1990, Iwama et al. 1993, Bertario et al. 
1994, Belchetz et al. 1996, Heiskanen et al. 2000, Bülow et al. 2003, Campos 
et al. 2010). 
6.3 Desmoid tumours and FAP (IV, V) 
Our prospective study on FAP screening among desmoid tumour patients 
found no new FAP cases. There were, however, three FAP patients who had 
initially been diagnosed because of desmoid tumour before the screening in 
the present prospective study. Consequently, the risk of FAP among the 
initially sporadic desmoid tumour patients was 4.8% in our study. 
 
We performed genetic testing for all patients who attended to study. Many of 
the previous studies are retrospective and possible FAP diagnosis had only 
been confirmed by endoscopy alone and in some cases this was only for 
symptomatic patients (Nieuwenhuis et al. 2011, Fallen et al. 2006). This 
approach may have missed some milder asymptomatic and possibly also 
almost apolypotic cases of AFAP. There are case reports that describe 
desmoid tumour patients with AFAP which had not been diagnosed by 
endoscopy because no polyps had been found at a young age, but gene 
mutation testing revealed an APC gene mutation (Bandipalliam et al. 2004, 
Benoit et al. 2007). A previous study about eight desmoid tumour patients 
with a family history of colon cancer found no APC germline mutations, and 
another study with 16 desmoid tumour patients found no APC mutations 
either (Giarola et al. 1998, Brueckl et al. 2005).  
 
Our study on the other hand found that 10% of the 221 desmoid tumour 
patients had FAP. Most of them were initially diagnosed with FAP and the 
desmoid tumour was detected later. Previous studies reported 8-16% of 
desmoid tumours to be associated with FAP (Fallen et al. 2006, Nieuwenhuis 
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et al. 2011). There might be some underestimation of the association of FAP 
and desmoids for two reasons: first not the all desmoid tumour patients will 
have undergone sufficient FAP screening, and second not all the desmoids 
among FAP patients are visible via non-invasive examinations when they 
locate as flat lesions in the intra-abdominal region. Incidental desmoids have 
been reported to exist among 13% of FAP patients, who underwent 
laparotomy (Hartley et al. 2004). FAP associated desmoids are 
predominantly intra-abdominal. They are diagnosed at a younger age and 
have an equal gender distribution.  Our data also show that FAP-related 
desmoid tumours are bigger, which has not been reported in previous studies 
(Fallen et al. 2006, Nieuwenhuis et al. 2011). Germline mutations in APC 
gene in FAP-related desmoid population tend to be located near to 3  end of 
the codon, i.e. after codon 1444 (Caspari et al. 1995, Leoz et al. 2015). 
Proportionally more mutations were located after codon 1444 among FAP-
related desmoid tumour patients than in FAP patients in general (Bertario et 
al. 2001, Lefevre et al. 2008). 
 
A predisposing factor such as surgical or other trauma or pregnancy, for 
desmoid tumour occurred in 39% of our patients with sporadic desmoid 
tumours, and in 64% of those with FAP related desmoid tumours. Previous 
reports of predisposing factor have been reported to exist among 34% of 
desmoid patients (Stoeckle et al. 2009). The risk of desmoid formation 
among FAP patients after surgical trauma is known. For example, Clark and 
colleagues reported 82% of FAP desmoid patients also had predisposing 
surgery and 59% of female FAP desmoid patients had a predisposing 
pregnancy (Clark et al. 1999).  It has also been demonstrated that incidental 
desmoids occurred in 3% of the first laparotomies, but accounted for as much 
as 30% in further laparotomies (Hartley et al. 2004). Nonetheless, 
abdominal surgery cannot be avoided among FAP patients, because of the 
otherwise inevitable colorectal cancer. Furthermore, when the surgery is 
postponed for too long due to a fear of desmoid, the desmoid tumour can 
also appear without surgical trauma and may even eventually prevent 
proctocolectomy and ileal pouch-anal anastomosis.  
 
Resections with clear margins were more common among sporadic desmoid 
patients in our series and intralesional resections were more common among 
FAP-related desmoid patients. The most likely explanation for this is that 
FAP-related desmoid tumours are bigger and have more difficult locations 
from the perspective of their total removal. Fourteen patients in our study 
were only followed-up without the need to be operated. The conservative 
management for FAP related intra-abdominal desmoids has also previously 
been recommended (Clark et al. 1999, Soravia et al. 2000, Nieuwenhuis et al. 
2011). Lately, this wait-and-see policy has become more common in desmoid 
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tumour treatment in general. Many series that describe the successful 
conservative management of sporadic desmoids have also been published 
(Bonvalot et al. 2008, Fiore et al. 2009, Bonvalot et al. 2013, Briand et al. 
2014, Burtenshaw et al. 2016).  
 
The recurrence rate in our patients was 26%. Among the FAP-related 
desmoids in our study the recurrence free survival at five years was 50%, but 
the number of the FAP-related desmoid recurrences was very small to draw 
definite conclusions. The recurrence free survival in sporadic desmoids was 
74% at five years and 72% at 10 and 20 years. Thus, it seems that recurrences 
occur shortly after the removal of the initial tumour. This has also been noted 
earlier. The median times for recurrences were reported to be in between 14 
and 22 months (Stoeckle et al. 2009, Mullen et al. 2012, Burtenshaw et al. 
2016). Other groups have reported recurrence rates that range between 23 
and 31% among both FAP-related and sporadic desmoids, and at five years 
recurrence free survival of 69% among sporadic desmoids (Heiskanen et al. 
1996, Stoeckle et al. 2009, Nieuwenhuis et al. 2011, Mullen et al. 2012, Crago 
et al. 2013, Ihalainen et al. 2015, He et al. 2015). There was a tendency 
towards lower recurrence rates among R0-resected tumours in our patient 
population. However, half of the R2-resected patients did not require any 
other treatment, which may mirror the nature of the course of the desmoid 
disease. Fourteen per cent of patients with FAP related desmoid, in our 
series, died because of desmoid tumour related complications. Desmoid 
tumours in St Marks’ hospital resulted in the death of 13% of FAP related 
desmoid tumour patients (Clark et al. 1999). Desmoid disease together with 
duodenal cancer is the second most common cause of death among FAP 
patients (de Campos et al. 2010).  
6.4 Limitations of the study 
The retrospective studies that are described in this dissertation compared 
surgical methods and survival. Such a retrospective approach has several 
inherent limitations regarding the interpretation of the results and the 
comparison made between the two operation techniques. Moreover, the 
analysis of the causes that led to secondary proctectomy was subject to bias 
because many of the operations were performed before the IPAA era, which 
began in 1992. From the time of starting IRA operations in the 1960s the 
evolution of overall surgical care pathways has been significant. This is why 
direct comparison of operations done over several decades may be limited. 
The data collection from the archival material is also a challenging task. All 
the information might not have been recorded as meticulously as it is 
nowadays.  In the desmoid studies the data were collected directly from the 
data files of the Pathology Department of Helsinki. For this reason, only the 
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biopsy confirmed desmoids were included. There might be patients with only 
radiographicly confirmed desmoid tumour especially among FAP patients, 
which are not included in our studies. The accurate histology or the sizes of 
the tumours and the information about the margins were not always 
available. Estimating the risk of FAP among initially sporadic desmoid 
patients in our prospective study was limited by the attendance rate, which 
was only 61% of all invited patients. Finally, patients with a hereditary 
syndrome are a specific population of colorectal patients. They usually have 
many relatives, who died of cancer and they might have their own prejudices 
and reasons about whether or not to have prophylactic treatment. Indeed, 
some patients postponed their attendance to screening because of the fear of 
the cancer and death.  
6.5 Future prospects 
FAP syndrome has been known about for almost 100 years, the development 
of all the treatment strategies over that time have changed the prognosis of 
patients. Colorectal cancer or permanent stomy are not inevitable results 
anymore. It is interesting to see how survival changes among the more 
recently diagnosed FAP patients, who have the chance of having current 
treatment from the beginning. It will also be interesting to see, if the 
extracolonic manifestations are more common causes of death in the future. 
Hopefully the treatment of intra-abdominal desmoids will develop in the 
future.  
 
Our next objective for future studies is to collect more data about the 
coverage of screening among FAP patients’ families. Another objective will be 
to study their survival and also the reasons why they have dropped-out from 
the screening programme. The screening for volunteer relatives will be 







The main findings of the present series of studies are as follows: 
 
1. IPAA should be the operation of choice for severe and intermediate 
polyposis, because it carries a better long-term survival without an 
increased risk of complications. The differences in survival between the 
two compared procedures are mainly due to the remaining 9% risk of 
rectal cancer death within the 30-year period after having the IRA 
operation despite the annual endoscopic follow-up of the rectum. Half of 
the patients with IRA ended up having a secondary proctectomy during 
their lifetime. Primary IPAA is also likely to succeed better than secondary 
IPAA. Only AFAP patients will be the candidates for IRA in the future. In 
the era of genetic testing, the phenotype should still play a major role in 
determining the operation technique. However, the family history and 
genotype should be taken account (I & II). 
 
2. The comparison of survival and mortality between call-ups and probands 
revealed that the overall survival was better among call-ups. The benefit 
remained whether the starting date of the survival analysis was the birth 
date or the date of the proband’s diagnosis or the participant’s own date of 
diagnosis (III). 
 
3. The desmoid tumour patients with abdominal symptoms or whose 
desmoid is located in a truncal region should routinely undergo FAP 
screening. Screening can be initiated with sigmoidoscopy, but if 
sigmoidoscopy is negative, the APC gene mutation testing should be 
considered (IV). 
 
4. FAP-related desmoids are more complex in their behaviour than sporadic 
desmoids. R0 resection should be a goal for treatment. If R0 resection is 
not possible, then the wait-and-see strategy might be the best alternative. 
Desmoid tumours are prone to recurrences even among sporadic 
desmoids, but the risk of death of desmoid tumour is still low among 
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